<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-title-group><journal-title>Alzheimer's &#x00026; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Elsevier, Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27490018</article-id><article-id pub-id-type="pmc">5399602</article-id><article-id pub-id-type="publisher-id">S1552-5260(16)30064-4</article-id><article-id pub-id-type="doi">10.1016/j.jalz.2016.06.004</article-id><article-categories><subj-group subj-group-type="heading"><subject>Featured Article</subject></subj-group></article-categories><title-group><article-title>METACOHORTS for the study of vascular disease and its contribution
to cognitive decline and neurodegeneration: An initiative of the Joint Programme for
Neurodegenerative Disease Research</article-title></title-group><contrib-group><contrib contrib-type="author"><collab>METACOHORTS Consortium<email>joanna.wardlaw@ed.ac.uk</email><contrib-group><contrib contrib-type="author"><name><surname>Dichgans</surname><given-names>Martin</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wardlaw</surname><given-names>Joanna</given-names></name></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Eric</given-names></name></contrib><contrib contrib-type="author"><name><surname>Zietemann</surname><given-names>Vera</given-names></name></contrib><contrib contrib-type="author"><name><surname>Seshadri</surname><given-names>Sudha</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sachdev</surname><given-names>Perminder</given-names></name></contrib><contrib contrib-type="author"><name><surname>Biessels</surname><given-names>Geert Jan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fazekas</surname><given-names>Franz</given-names></name></contrib><contrib contrib-type="author"><name><surname>Benavente</surname><given-names>Oscar</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pantoni</surname><given-names>Leonardo</given-names></name></contrib><contrib contrib-type="author"><name><surname>De Leeuw</surname><given-names>Frank-Erik</given-names></name></contrib><contrib contrib-type="author"><name><surname>Norrving</surname><given-names>Bo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Matthews</surname><given-names>Paul</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Christopher</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mok</surname><given-names>Vincent</given-names></name></contrib><contrib contrib-type="author"><name><surname>D&#x000fc;ring</surname><given-names>Marco</given-names></name></contrib><contrib contrib-type="author"><name><surname>Whiteley</surname><given-names>Will</given-names></name></contrib><contrib contrib-type="author"><name><surname>Shuler</surname><given-names>Kirsten</given-names></name></contrib><contrib contrib-type="author"><name><surname>Alonso</surname><given-names>Alvaro</given-names></name></contrib><contrib contrib-type="author"><name><surname>Black</surname><given-names>Sandra E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Brayne</surname><given-names>Carol</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chabriat</surname><given-names>Hugues</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cordonnier</surname><given-names>Charlotte</given-names></name></contrib><contrib contrib-type="author"><name><surname>Doubal</surname><given-names>Fergus</given-names></name></contrib><contrib contrib-type="author"><name><surname>Duzel</surname><given-names>Emrah</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ewers</surname><given-names>Michael</given-names></name></contrib><contrib contrib-type="author"><name><surname>Frayne</surname><given-names>Richard</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hachinski</surname><given-names>Vladimir</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ikram</surname><given-names>Mohammad Arfan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jessen</surname><given-names>Frank</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jouvent</surname><given-names>Eric</given-names></name></contrib><contrib contrib-type="author"><name><surname>Linn</surname><given-names>Jennifer</given-names></name></contrib><contrib contrib-type="author"><name><surname>O'Brien</surname><given-names>John</given-names></name></contrib><contrib contrib-type="author"><name><surname>van Oostenbrugge</surname><given-names>Robert</given-names></name></contrib><contrib contrib-type="author"><name><surname>Malik</surname><given-names>Rainer</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mazoyer</surname><given-names>Bernard</given-names></name></contrib><contrib contrib-type="author"><name><surname>Schmidt</surname><given-names>Reinhold</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sposato</surname><given-names>Luciano A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stephan</surname><given-names>Blossom</given-names></name></contrib><contrib contrib-type="author"><name><surname>Swartz</surname><given-names>Richard H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vernooij</surname><given-names>Meike</given-names></name></contrib><contrib contrib-type="author"><name><surname>Viswanathan</surname><given-names>Anand</given-names></name></contrib><contrib contrib-type="author"><name><surname>Werring</surname><given-names>David</given-names></name></contrib><contrib contrib-type="author"><name><surname>Abe</surname><given-names>Koji</given-names></name></contrib><contrib contrib-type="author"><name><surname>Allan</surname><given-names>Louise</given-names></name></contrib><contrib contrib-type="author"><name><surname>Arba</surname><given-names>Francesco</given-names></name><role>on behalf of the VISTA Collaboration: H.-C. Diener (Chair), S. Davis, G. Hankey, K.R. Lees, B. Ovbiagele, C. Weir</role></contrib><contrib contrib-type="author"><name><surname>Bae</surname><given-names>Hee-Joon</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bath</surname><given-names>Philip MW.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bordet</surname><given-names>Regis</given-names></name></contrib><contrib contrib-type="author"><name><surname>Breteler</surname><given-names>Monique</given-names></name></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Seong</given-names></name></contrib><contrib contrib-type="author"><name><surname>Deary</surname><given-names>Ian</given-names></name></contrib><contrib contrib-type="author"><name><surname>DeCarli</surname><given-names>Charles</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ebmeier</surname><given-names>Klaus</given-names></name></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Lei</given-names></name></contrib><contrib contrib-type="author"><name><surname>Greenberg</surname><given-names>Steven M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ihara</surname><given-names>Masafumi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kalaria</surname><given-names>Rajesh</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>SanYun</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lim</surname><given-names>Jae-Sung</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lindley</surname><given-names>Richard I.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mead</surname><given-names>Gillian</given-names></name></contrib><contrib contrib-type="author"><name><surname>Murray</surname><given-names>Alison</given-names></name></contrib><contrib contrib-type="author"><name><surname>Quinn</surname><given-names>Terry</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ritchie</surname><given-names>Craig</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sacco</surname><given-names>Ralph</given-names></name></contrib><contrib contrib-type="author"><name><surname>Al-Shahi Salman</surname><given-names>Rustam</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sprigg</surname><given-names>Nikola</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sudlow</surname><given-names>Cathie</given-names></name></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Alan</given-names></name></contrib><contrib contrib-type="author"><name><surname>van Boxtel</surname><given-names>Martin</given-names></name></contrib><contrib contrib-type="author"><name><surname>van der Grond</surname><given-names>Jeroen</given-names></name></contrib><contrib contrib-type="author"><name><surname>van der Lugt</surname><given-names>Aad</given-names></name></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Yuan-Han</given-names></name></contrib></contrib-group></collab><xref rid="fn1" ref-type="fn">1</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. Tel.: +44-131-465-9570</corresp><fn id="fn1"><label>1</label><p id="ntpara0020">A full listing of the authors for this
manuscript can be found in the <xref rid="appsec1" ref-type="sec">appendix</xref> at the end of this
article.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>1</day><month>12</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.--><pub-date pub-type="ppub"><month>12</month><year>2016</year></pub-date><volume>12</volume><issue>12</issue><fpage>1235</fpage><lpage>1249</lpage><permissions><copyright-statement>&#x000a9; 2016 The Authors</copyright-statement><copyright-year>2016</copyright-year><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><p>Dementia is a global problem and major target for
health care providers. Although up to 45% of cases are primarily or partly due
to cerebrovascular disease, little is known of these mechanisms or treatments
because most dementia research still focuses on pure Alzheimer's disease. An
improved understanding of the vascular contributions to neurodegeneration and
dementia, particularly by small vessel disease, is hampered by imprecise data,
including the incidence and prevalence of symptomatic and clinically &#x0201c;silent&#x0201d;
cerebrovascular disease, long-term outcomes (cognitive, stroke, or functional),
and risk factors. New large collaborative studies with long follow-up are
expensive and time consuming, yet substantial data to advance the field are
available. In an initiative funded by the Joint Programme for Neurodegenerative
Disease Research, 55 international experts surveyed and assessed available data,
starting with European cohorts, to promote data sharing to advance understanding
of how vascular disease affects brain structure and function, optimize methods
for cerebrovascular disease in neurodegeneration research, and focus future
research on gaps in knowledge. Here, we summarize the results and
recommendations from this initiative. We identified data from over 90 studies,
including over 660,000 participants, many being additional to neurodegeneration
data initiatives. The enthusiastic response means that cohorts from North
America, Australasia, and the Asia Pacific Region are included, creating a truly
global, collaborative, data sharing platform, linked to major national dementia
initiatives. Furthermore, the revised World Health Organization International
Classification of Diseases version 11 should facilitate recognition of
vascular-related brain damage by creating one category for all cerebrovascular
disease presentations and thus accelerate identification of targets for dementia
prevention.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Dementia</kwd><kwd>Cerebrovascular disease</kwd><kwd>Small vessel disease</kwd><kwd>Neurodegeneration, Cohorts, Survey</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p>Worldwide, nearly 36 million people are estimated to be living
with dementia. This is expected to triple by 2050. Cerebrovascular disease
causes up to 45% of all dementias alone or in conjunction with Alzheimer's
disease (AD) <xref rid="bib1" ref-type="bibr">[1]</xref>, <xref rid="bib2" ref-type="bibr">[2]</xref>. Despite vascular risk factor reduction being an
achievable target for public health intervention in many countries, and some
recent evidence of success in preventing dementia <xref rid="bib3" ref-type="bibr">[3]</xref>, knowledge about vascular contributions
to dementia remains modest.</p><p>Many studies, from the early 1990s onward <xref rid="bib4" ref-type="bibr">[4]</xref>, have demonstrated that
cognitive impairment and dementia are both common and under-recognized after
stroke <xref rid="bib5" ref-type="bibr">[5]</xref>. The
concept of &#x0201c;vascular cognitive impairment&#x0201d; was introduced in 1994 <xref rid="bib6" ref-type="bibr">[6]</xref>, covering a spectrum of
cognitive impairment after stroke to cognitive impairment in association with
otherwise asymptomatic cerebrovascular disease. The most common vascular
contributor to dementia is cerebral small vessel disease (SVD) <xref rid="bib7" ref-type="bibr">[7]</xref>, a condition that affects
perforating vessels, thence white and gray matter, and accelerates
neurodegenerative processes. Vascular dementia reflects the global effects of
vascular disease on the brain, not just of multiple individual infarcts.
<xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref> It
results in stroke, cognitive decline and dementia, plus neuropsychiatric
symptoms, gait, balance <xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>, and continence problems <xref rid="bib10" ref-type="bibr">[10]</xref>, necessitating a larger framework for
targeted, comprehensive studies <xref rid="bib11" ref-type="bibr">[11]</xref>.</p><p>In 2006, the National Institute for Neurological Disorders and
Stroke and the Canadian Stroke Network convened a multidisciplinary research
group to recommend standards for the study of vascular cognitive impairment
<xref rid="bib11" ref-type="bibr">[11]</xref>. In 2013
the Alzheimer's Association convened an expert working group, which summarized
the state of vascular cognitive impairment science and identified areas where
new knowledge is needed <xref rid="bib12" ref-type="bibr">[12]</xref>. However, despite strong and unanimous evidence for the
major burden of vascular cognitive impairment on both patients and their
caregivers <xref rid="bib13" ref-type="bibr">[13]</xref>,
most dementia research largely overlooks vascular disease as a cause. In part,
this reflects that clinicians and researchers working on dementia, stroke,
physical, or psychiatric manifestations are still too often segregated. &#x0201c;Stroke&#x0201d;
and &#x0201c;dementia&#x0201d; (both syndromes, not pathological diagnoses) present to different
clinical specialists (<xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>); stroke specialists
under-recognize the cognitive impact of stroke, whereas dementia specialists
under-recognize vascular inputs to dementia pathophysiology. This separation
also affects research and funding initiatives, for example, vascular disease was
rarely mentioned in a report on 169 European studies considered relevant to
neurodegenerative disease research <xref rid="bib14" ref-type="bibr">[14]</xref>. Better diagnostic criteria for the different cognitive
profiles of vascular and AD are also needed <xref rid="bib15" ref-type="bibr">[15]</xref>.</p><p>The recognition of an important role for cerebrovascular disease
in dementia opens major therapeutic opportunities. Vascular risk factor
reduction and stroke prevention may already be reducing dementia incidence
<xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib16" ref-type="bibr">[16]</xref>.
Increased government and public concern about dementia, as well as better
grouping of codes for different cerebrovascular disease presentations in the
revised International Classification of Disease (ICD) codes version 11 (ICD-11,
release 2018, <ext-link ext-link-type="uri" xlink:href="http://www.who.int/classifications/icd/revision/en/" id="intref0010">http://www.who.int/classifications/icd/revision/en/</ext-link>), will
help advance understanding of cerebrovascular disease and its impact on
neurodegeneration.</p><p>Here, we report on an initiative funded by the JPND to promote
efficient use of available data in which we identified information, relevant to
vascular disease, available in different types of studies that could provide
large, statistically robust, generalizable data sets, and create platforms for
future mechanistic, epidemiological research, or clinical trials <xref rid="bib17" ref-type="bibr">[17]</xref>. We used the exemplar
survey data to identify major gaps in knowledge, methodological issues and
suggest priority actions to advance the field.</p></sec><sec id="sec2"><label>2</label><title>Method</title><p>We convened a group of experts in stroke and cerebrovascular
disease, AD, epidemiology, psychology, neuroimaging, and clinical trials
(<xref rid="appsec2" ref-type="sec">Appendix</xref>). We
designed a survey aiming to capture information about data available in cohorts
relevant to vascular contributions to neurodegeneration. A &#x0201c;relevant cohort&#x0201d;
could comprise patients with stroke/transient ischaemic attack (TIA), or
suspected cognitive impairment or dementia, or healthy subjects, from a hospital
or geographical population, and would have information on vascular disease
and/or risk factors, and one or more of the following: cognitive data, long-term
outcomes (including physical function and mood), neuroimaging including
biomarkers of vascular disease and/or neurodegeneration, physiological measures
(e.g., blood pressure, vascular stiffness), or biomarker samples with a relevant
vascular link. The study could be completed or ongoing, cross-sectional or
longitudinal, observational, or a clinical trial. The minimum sample for
inclusion was 50 participants, with no age or geographical limits.</p><p>The survey (<xref rid="appsec2" ref-type="sec">Supplementary Material</xref>), designed for online delivery,
sought information on whether participants were healthy or recruited from a
stroke or memory or other relevant clinic or participated in a clinical trial.
Data were collected on demographics, medical history, risk factors, cognition,
brain imaging, physiological measures, comorbidities at inclusion, duration and
frequency of follow-up, follow-up assessments, outcome events, whether the study
was completed or ongoing, availability of bio- or genetic samples for further
analysis, interest of investigators in data sharing, and whether approvals for
sharing were already in place.</p><p>The survey was piloted by three members of the expert group
(JMW, MD, and ES), before being distributed widely. It ran from November 15,
2014 until August 31, 2015 with updates for ongoing studies to November 2015. We
initially invited participation from investigators of studies in Europe through
the JPND Vascular Disease group, relevant studies listed in the JPND report
<xref rid="bib14" ref-type="bibr">[14]</xref>, networks,
and studies known to them, for example, Dementia Platform UK, the German Center
for Neurodegenerative Diseases (DZNE), and &#x0201c;Constances&#x0201d; in France; however,
investigators based in North America, Australasia, and the Asia Pacific Region
also expressed interest and were included. We recognized that the survey was
unlikely to capture all studies but aimed to capture a broad sample,
particularly from the vascular disease perspective (including clinical trials),
as these are under-represented in other dementia initiatives <xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib18" ref-type="bibr">[18]</xref>, <xref rid="bib19" ref-type="bibr">[19]</xref>, <xref rid="bib20" ref-type="bibr">[20]</xref>.</p><p>We performed descriptive statistics and meta-analyses (random
effects methods) <xref rid="bib21" ref-type="bibr">[21]</xref>. For detailed analyses of cognition in relation to
stroke, we used studies that collected data on stroke and cognition from
subjects without prestroke dementia in community-based studies or in subjects
with stroke (hospital-based post-stroke cognitive impairment cohorts). Responses
were received from 68 investigators (some provided data on several studies).
Samples were updated to include ongoing recruitment to December 01, 2015. Five
incomplete responses were removed from further analysis (for full details, see
<xref rid="appsec2" ref-type="sec">Supplementary
Material</xref>).</p><p>Fifty-five experts (<xref rid="appsec2" ref-type="sec">Appendix</xref>) discussed the data to identify
knowledge gaps requiring new data, implications of ICD-11 disease codes
(<ext-link ext-link-type="uri" xlink:href="http://www.who.int/classifications/icd/revision/en/" id="intref0015">http://www.who.int/classifications/icd/revision/en/</ext-link>), agree
early targets for shared data analysis, and plan future&#x000a0;analyses of existing
data and new research initiatives.</p></sec><sec id="sec3"><label>3</label><title>Results</title><p>The survey collected data on a total of 96 studies, including
167,064 participants, or 667,064 with UK Biobank <xref rid="bib22" ref-type="bibr">[22]</xref> (186,000 and 686,000, respectively
including target samples in ongoing studies; <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>;
<xref rid="appsec2" ref-type="sec">Supplementary
Table&#x000a0;1</xref>). The sample size ranged from 41 to 29,852 (excluding
UK Biobank). The mean age was 72, range 15 to 106&#x000a0;years. There were 84
observational studies (11 cross sectional and 73 longitudinal) and 12 randomized
clinical trials. The main types of studies overlapped (some recruited from
several sources by various methods, <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>) but, in general,
most studies could be attributed to the following categories: community-based
cohorts including population studies (32 studies, of which 28 were suitable for
analyzing incident post-stroke dementia, sample size &#x0003e;600,000 subjects),
hospital-based stroke clinics (i.e., stroke and TIA services, 26 studies, 12
suitable for analyzing incident post-stroke dementia, &#x0223c;4700 subjects),
hospital-based memory clinics (15 studies, &#x0223c;20,000 subjects), and randomized
clinical trials (12 trials, &#x0223c;20,000 subjects); 38 studies were ongoing
(recruiting or long-term follow-up, <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). Some studies recruiting from mixed sources
(<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>,
<xref rid="appsec2" ref-type="sec">Supplementary
Table&#x000a0;1</xref>) were not included in detailed analysis in the
following section (or in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>), yet provide other relevant information (details in
<xref rid="appsec2" ref-type="sec">Supplementary
Material</xref>). The longest duration of follow-up so far was more
than 5 years (<xref rid="fig2" ref-type="fig">Fig.&#x000a0;2</xref>). Sixty-seven studies
were based in Europe, 17 in North America, and 12 in the Asia Pacific Region
(excluding 2 incomplete entries).</p><p>Most cohorts (&#x0223c;86/96) did neither appear in the JPND report of
169 cohort studies <xref rid="bib14" ref-type="bibr">[14]</xref> nor overlap by more than 20% with other recent
initiatives, for example, Cohort Studies of Memory in an International
Consortium (COSMIC) <xref rid="bib18" ref-type="bibr">[18]</xref>, Virtual International Stroke Trials Archive (VISTA)
Cognition <xref rid="bib22" ref-type="bibr">[22]</xref>, or
the Consortium of Studies of Post-Stroke Cognitive Decline and Dementia
(STROKOG; <xref rid="bib23" ref-type="bibr">[23]</xref>).
This lack of overlap indicates a gap in information about vascular disease in
neurodegeneration when viewed from &#x0201c;traditional&#x0201d; neurodegenerative perspectives
and shows that there is a large amount of data available for sharing and
meta-analyses if it could be brought together efficiently and
effectively.</p><sec id="sec3.1"><label>3.1</label><title>Data sources</title><sec id="sec3.1.1"><label>3.1.1</label><title>Community cohorts</title><p>Community-based (including population-based) cohorts are
the best way to determine the relative contribution of vascular and
other pathologies to the development of dementia and cognitive aging.
They permit assessment of risk factor levels
<italic>before</italic> the development of cognitive
impairment or dementia, and hence, risk factor measurement is less
likely to be affected by disease or its treatment. These cohorts often
have repeated measures, starting in midlife, so, the impact of
cumulative exposures, including during specific ages, can be explored.
In contrast, clinical studies usually recruit from one extreme of the
population distribution of vascular susceptibility; these studies may
generate hypotheses that can be tested in population-based
cohorts.</p><p>We gathered data from a representative sample of 32
community-based cohorts (<xref rid="appsec2" ref-type="sec">Supplementary Table&#x000a0;1</xref>, <xref rid="appsec2" ref-type="sec">Supplementary Fig.&#x000a0;1</xref>; 28 suitable
for analysis) that defined the extent of vascular compromise, and
structural brain injury in each person using serial brain imaging, and
also measured global and domain-specific cognitive performance, mood,
and physical function. Most studies prospectively followed their
participants using health record linkage, questionnaires, or repeated
examinations, to detect progression to cognitive impairment, stroke, or
dementia. Most studies include biobanking, and a few have prospective
postmortem brain banks. The community-based studies were either
geographically population-based or recruited through advertisement and
other strategies.</p><p>Most studies were conducted in the past three decades in
North America and Europe, studied older participants (mean age
70&#x000a0;years), and used brain magnetic resonance imaging (MRI). Sample size
ranged from around 100 to 500,000 participants (median: 1400; Q1&#x02013;Q3:
400&#x02013;9500), with imaging planned for &#x0223c;150,000. However, there are
limitations. The imaging protocols, hence sensitivity to vascular
pathology, varied, particularly in the older studies. Vascular risk
factor assessment covered common risk factors, but interim TIA, clinical
stroke, and stroke subtype were ascertained with varying degrees of
rigor ranging from surveillance for incident events with direct
participant examination and consensus review by study investigators,
through medical records linkage, to self-reported events. Data on
lipids, inflammatory markers, and renal function were missing from about
half the studies. There was considerable variation in methods and timing
used to assess vascular and cognitive outcomes. Data from a wider age
span starting in youth to mid adulthood, diverse race, ethnic, and
geographic origins, but using common protocols for cognition, physical
function, minimum standard physiological measures, and MRI, are
needed.</p></sec><sec id="sec3.1.2"><label>3.1.2</label><title>Post-stroke cognitive impairment
cohorts</title><p>In hospital-based series, about 20% of stroke patients
have dementia after stroke, and the cumulative incidence of dementia
after the first year is about 3% pa <xref rid="bib24" ref-type="bibr">[24]</xref>. The survey identified 26
hospital-based cohorts recruiting from stroke/TIA &#x000b1; other services
(<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). Twelve had data suitable for analysis
comprising studies that recruited patients presenting to hospital with
ischemic stroke or TIA, followed longitudinally with cognitive and other
measures. These studies collectively included &#x0003e;4134 subjects
currently (planned &#x0003e;4700), and nearly 90% have structural
neuroimaging. Most assessed educational attainment (although few
assessed premorbid intelligence quotient), most used the Montreal
Cognitive Assessment (MoCA) and all collected details of vascular
disease and vascular risk factors (<xref rid="appsec2" ref-type="sec">Supplementary Fig.&#x000a0;2</xref>). Of note,
several cohorts include amyloid-positron emission tomography imaging,
thus enabling assessment of the interactions between vascular and
amyloid pathology in cognitive decline.</p><p>These data, if combined, would help overcome many gaps
in knowledge remaining from previous post-stroke cognitive impairment
studies <xref rid="bib5" ref-type="bibr">[5]</xref>, <xref rid="bib25" ref-type="bibr">[25]</xref>: poor generalizability due to small sample
and inclusion of high-functioning ischemic, nondysphasic, stroke
patients, with an informant; or various entry restrictions, for example,
inclusion of TIAs only, or first-only strokes, rather than any stroke.
The variety of cognitive, physical, and physiological assessment tools
and lack of prestroke cognition or contemporaneous mood data restrict
comparisons. There is little information on concomitant AD pathology, or
on biomarkers of vascular dementia, or pathology specimens to determine
true proportions of vascular disease, and imaging acquisitions vary. As
with population studies, agreed standards for future studies would
increase research efficiency.</p></sec><sec id="sec3.1.3"><label>3.1.3</label><title>Memory clinics</title><p>Patients attending a memory clinic represent a highly
relevant population to study vascular contributions to cognitive decline
and dementia. Most patients attending memory clinics have vascular
lesions co-occurring with other pathologies, in particular,
Alzheimer-type processes. However, there is limited evidence from
longitudinal studies and randomized controlled trials (RCTs) in memory
clinic-based cohorts to determine how much the vascular lesions
contribute to cognitive profiles, predict prognosis, or should influence
treatment. Extrapolation of observations from, for example,
population-based studies, may not be valid because disease predictive
factors in a relatively healthy population may not necessarily predict
disease progression among individuals affected by the disease, or vice
versa.</p><p>We identified 15 cohorts that included memory clinic
patients (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>, <xref rid="appsec2" ref-type="sec">Supplementary Fig.&#x000a0;3</xref>), some
providing data only on memory <xref rid="bib26" ref-type="bibr">[26]</xref>, whereas others included other
clinical presentations <xref rid="bib27" ref-type="bibr">[27]</xref>. Cohort sizes were generally modest, with 8 of
15 cohorts including &#x02264;200 patients, although baseline data are available
on 19,144 patients of mean age of 73&#x000a0;years. All studies collected data
on demographics, risk factors for vascular disease including education.
Cognitive test results and neuroimaging (mostly MRI or computed
tomography) were available from most patients in all cohorts. However,
diagnostic criteria for mild cognitive impairment (MCI) and dementia,
and its subtypes, varied across cohorts. Moreover, although most of the
studies collected longitudinal data, both timing and content of
follow-up varied substantially.</p><p>Unfortunately, substantial gaps in knowledge remain,
such as the extent to which different pathologies may have differential
prognostic impact in different stages of the dementia process. For
example, larger studies at different disease stages across multiple
clinics would help to determine if white matter hyperintensity (WMH)
burden is indeed a stronger predictor of progressive brain atrophy in
people with MCI and early AD than in later stages <xref rid="bib28" ref-type="bibr">[28]</xref>, <xref rid="bib29" ref-type="bibr">[29]</xref>.
Further studies are needed to determine how much co-occurring
pathologies affect risk-benefit ratios of treatments that are typically
used to reduce vascular risk, such as antithrombotic drugs. For example,
randomized trials of aspirin in patients with AD observed rates of
intracerebral hemorrhage that were much higher than those in people
without AD <xref rid="bib30" ref-type="bibr">[30]</xref>.</p></sec><sec id="sec3.1.4"><label>3.1.4</label><title>Physical function</title><p>Gait and balance disorders are common in elderly people,
increasing rapidly from around 15% at the age of 60 years to &#x0003e;50% at
age of &#x02265;80&#x000a0;years <xref rid="bib31" ref-type="bibr">[31]</xref>, <xref rid="bib32" ref-type="bibr">[32]</xref>, <xref rid="bib33" ref-type="bibr">[33]</xref>. They are often
multifactorial and increase falls, institutionalization, and mortality
<xref rid="bib31" ref-type="bibr">[31]</xref>, <xref rid="bib32" ref-type="bibr">[32]</xref>, <xref rid="bib34" ref-type="bibr">[34]</xref>. For example, Parkinson's disease,
impairs gait, and balance <xref rid="bib35" ref-type="bibr">[35]</xref>, but vascular cerebral disorders also disturb
gait and may contribute to Parkinsonian symptoms <xref rid="bib36" ref-type="bibr">[36]</xref>, <xref rid="bib37" ref-type="bibr">[37]</xref>,
particularly in SVD where gait is the second commonest symptom after
cognitive disturbance <xref rid="bib38" ref-type="bibr">[38]</xref>, <xref rid="bib39" ref-type="bibr">[39]</xref>. The Leukoaraiosis and
Disability in the Elderly Study (LADIS) showed that gait and balance
were correlated with WMH severity <xref rid="bib8" ref-type="bibr">[8]</xref>. As gait represents a complex
higher order form of motor functioning, impaired gait and cognition are
closely intertwined <xref rid="bib31" ref-type="bibr">[31]</xref>.</p><p>However, gait and balance were rarely assessed in
population-based or hospital-based post-stroke or memory studies. The
survey found very limited information, but such details were poorly
captured in the questionnaire. For example, none of five studies from
general geriatric clinics mentioned recording gait, walking, or
movement. Under &#x0201c;other,&#x0201d; no study mentioned these words either. Seven
other studies mentioned &#x0201c;gait&#x0201d; (<xref rid="appsec2" ref-type="sec">Supplementary Table&#x000a0;1</xref>, ABC1936,
ABC1921, CASPER, ONDRI, PURE-MIND, RUN DMC, STRIDE) although we
recognize that some studies that did not specifically mention gait do
collect such data. This suggests that problems of gait and balance are
under-recognized compared with other features of vascular
neurodegeneration and hence are poorly assessed in vascular-focused
clinics for older people, despite representing a major problem for older
people, their families, hospitals, and social services.</p></sec><sec id="sec3.1.5"><label>3.1.5</label><title>Clinical trials</title><p>Many acute stroke and stroke prevention RCTs have not
collected cognitive data because of the following: (1) they focused on
the physical consequences of stroke; (2) cognitive testing was
considered too laborious and not applicable to participants whose
vision, speech, or hand function were impaired; or (3) there was no
informant, thus excluding significant proportions of patients from
testing <xref rid="bib40" ref-type="bibr">[40]</xref>.</p><p>The survey collected data from 12 RCTs, testing
treatments for acute ischemic or hemorrhagic stroke or secondary
prevention of ischemic stroke (<xref rid="appsec2" ref-type="sec">Supplementary Table&#x000a0;1</xref>). The sample
size ranged from 41 to 4750, total current sample 20,035 (planned sample
22,314), of which 12,439 will have detailed neuroimaging. The mean
participant age is 71.6&#x000a0;years, and 58.5% are men. Most trials
consistently recorded baseline vascular risk factors including blood
pressure, and outcomes such as recurrent vascular events and functional
outcome assessed using the modified Rankin Scale. However, cognitive
tests varied (eight used the mini-mental state examination [MMSE], one
the MoCA, five the Telephone Interview of Cognitive Assessment (TICS),
and two a more detailed assessment), none tested premorbid intelligence
quotient although four trials recorded educational attainment, few
assessed mood, and none corrected for imaging features such as WMH
burden (a predictor of post-stroke cognitive impairment). The latest
follow-up was at 12&#x000a0;months in all but two trials (latest assessment 24
and 36&#x000a0;months in one trial each), substantially shorter than that in the
other study types (<xref rid="fig2" ref-type="fig">Fig.&#x000a0;2</xref>).</p><p>An individual patient data meta-analysis of cognition
after stroke in these trials, which are typical of many stroke treatment
or prevention trials, would be hampered by lack of consistency in
cognitive measures and of long-term data, despite providing exemplary
vascular risk factor and vascular outcome assessments. Inadequate
attention has been given to assessing cognition after stroke in RCTs to
date. Agreement on pragmatic and rapid ways to assess important
cognitive domains such as executive function and processing speed, not
just memory, and to correct for premorbid cognition, depression, and WMH
burden on imaging, are essential to advance understanding of cognitive
trajectories after stroke. There is an opportunity to progress by
including cognitive tests in ongoing multicentre stroke trials where
feasible as pragmatic methods are becoming available.</p></sec></sec><sec id="sec3.2"><label>3.2</label><title>Methods for assessing vascular effects on
cognition and neurodegeneration</title><p>Vascular disease requires different methods compared with
other types of neurodegeneration or dementia research. Two key methods,
which differ substantially in their requirements for vascular disease and
neurodegenerative pathologies such as AD, are the assessment of neuroimaging
and cognition. Integrated cerebrovascular disease codes are essential to
bridge clinical presentations. All are discussed here.</p><sec id="sec3.2.1"><label>3.2.1</label><title>Imaging, protocols, and analysis
methods</title><p>In the 1990s, landmark neuroepidemiological studies
showed that clinically silent cerebrovascular lesions detected only on
MRI, including lacunes and WMH of presumed vascular origin, were
associated with cognitive impairment and an increased risk of future
stroke and dementia <xref rid="bib41" ref-type="bibr">[41]</xref>, <xref rid="bib42" ref-type="bibr">[42]</xref>. More recent studies have incorporated
advanced imaging modalities that interrogate physiological and molecular
changes&#x02014;such as structural and functional connectivity with diffusion
tensor imaging and functional MRI, cerebral perfusion, and molecular
markers such as amyloid deposition&#x02014;with larger sample sizes to increase
statistical power for subgroup analyses and to predict clinical
events.</p><p>Our synthesis of cohort studies identified many
participants in community-dwelling settings and clinical studies on
stroke who have cognitive data and undergone or will undergo
neuroimaging, predominantly brain MRI (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>, <xref rid="appsec2" ref-type="sec">Supplementary
Table&#x000a0;1</xref>). We identified five major areas where there
are currently limitations, gaps in knowledge, or unrealized
opportunities for harmonization and collaboration of neuroimaging
methods.</p><p>First, vascular lesion definitions and terminology
require standardization, to enable cross-cohort comparisons and
meta-analysis. This need has largely been met by the recent STandards
for ReportIng Vascular ChangEs Neuroimaging (STRIVE) <xref rid="bib44" ref-type="bibr">[44]</xref>; however, updates
will become necessary for new neuroimaging methods that bring new
imaging markers or increased sensitivity of known markers.</p><p>Second, to harmonize and compare findings across
studies, full details of neuroimaging acquisition and analysis methods
should be reported. New studies could adopt successful, validated
methods recommended by STandards for ReportIng Vascular ChangEs
Neuroimaging or used previously if the full methodological details were
available. Imaging protocols could be shared through a single, publicly
available website.</p><p>Third, reliability and accuracy of lesion classification
would be improved through sharing of (exemplary) MRI data across cohorts
with appropriate anonymization. For visual rating, a shared MRI
repository could be used to train new raters using expert consensus as
the gold standard. For computational analysis, for example, of MRI WMH,
a repository could allow developers access to MRI images showing a range
of lesions, from different vendors and field strengths, to derive or
validate processing methods.</p><p>Fourth, there is great need for integrating information
on vascular and neurodegenerative pathology from cohorts recruited
through different settings, leveraging the expertise of stroke and
dementia specialists in vascular and neurodegenerative disease.
Integrating data across geographic and race/ethnic backgrounds would
also help to more reliably identify and explore differences in
subclinical vascular brain injury.</p><p>Fifth, more collaboration would enhance innovative
methods for neuroimaging post-processing and data analysis. One example
is the increasing emphasis on integrated data analysis to determine
total SVD burden and effects on brain connectivity, neurodegeneration,
and cognition (<xref rid="fig3" ref-type="fig">Fig.&#x000a0;3</xref>). Advances in
machine learning and graph theory&#x02013;based network analysis provide new
opportunities to accelerate image analysis for large-scale studies. A
multidisciplinary approach including neuroepidemiologists and clinical
researchers on the one hand, and computer scientists, mathematicians and
biomedical engineers on the other hand, is required.</p></sec><sec id="sec3.2.2"><label>3.2.2</label><title>Cognition</title><p>There are particular challenges in the assessment of
cognition in patients with cerebrovascular diseases, rendering detailed
neuropsychological approaches (typically used in studies of dementia)
impractical. Fatigue is common after stroke, limiting patient tolerance
of prolonged tests. Patients may have dysphasia, impaired hand function,
or visual deficits, making some tests impossible, even if comprehension
is preserved. Depression and apathy are common in SVD and affect
cognitive test performance. Many brief cognitive screening tests focus
on memory, although vascular disease, in particular SVD, typically
results in <italic>subcortical</italic> cognitive impairments, for
example, loss of frontal and executive function <xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib43" ref-type="bibr">[43]</xref>, and may
occur in a stepwise manner reflecting sudden vascular events.</p><p>The survey shows huge variability in cognitive outcome
measures in stroke/TIA patients (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>, <xref rid="appsec2" ref-type="sec">Supplementary
Material</xref>). About 25% of studies used a diagnosis of
dementia or MCI, another 25% used a single cognitive test (most commonly
MoCA, MMSE, or the revised Addenbrooke's cognitive examination); less
than 10% assessed the premorbid (i.e., optimal early adulthood)
cognitive status; and few assessed cognition immediately before the
stroke. Of cognitive domains assessed in these studies, there was an
almost equal distribution among memory, executive functions, reaction
time, visuospatial function, with many accounting also for depression
and anxiety.</p><p>Longitudinal observational studies included patients
with different cognitive impairment or dementia diagnoses, but of note,
about half the studies did not assign a specific dementia type and the
diagnostic criteria for MCI, AD, vascular cognitive impairment (VCI),
and dementia varied. The most commonly used criteria were the National
Institutes of Aging-Alzheimer's Association for MCI and AD,
<italic>Diagnostic and Statistical Manual of Mental Disorders, IV
Edition</italic> for dementia, and the American Heart
Association/American Stroke Association for VCI. However, with the
exception of the widely used <italic>Diagnostic and Statistical
Manual of Mental Disorders, IV Edition</italic> criteria for
dementia, most studies used widely differing criteria for other
categories of cognitive disorders, perhaps reflecting the difficulties
and complexity of cognitive assessment in vascular disease. Most
community-based and longitudinal observational studies used the MMSE,
which is insensitive to vascular cognitive decline. A stepwise approach
to determining the cognitive test approach to vascular disease is
suggested in <xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>.</p><p>The importance of assessing cognitive profiles (without
worsening the complexity of categorization) is emphasized by recent
findings in SVD patients of memory loss (a cortical dysfunction)
<xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib44" ref-type="bibr">[44]</xref>, suggesting that SVD affects not just white
and deep gray matter but also the (connected) cerebral cortex
(<xref rid="fig3" ref-type="fig">Fig.&#x000a0;3</xref>)
<xref rid="bib45" ref-type="bibr">[45]</xref>, <xref rid="bib46" ref-type="bibr">[46]</xref>, <xref rid="bib44" ref-type="bibr">[44]</xref>. Lower connectivity within cerebral
networks was associated with cognitive impairment and dementia
<xref rid="bib47" ref-type="bibr">[47]</xref>, <xref rid="bib48" ref-type="bibr">[48]</xref>; WMHs were associated with less brain
activation in the frontal cortex on fludeoxyglucose-positron emission
tomography <xref rid="bib49" ref-type="bibr">[49]</xref>, <xref rid="bib50" ref-type="bibr">[50]</xref>, <xref rid="bib51" ref-type="bibr">[51]</xref>. Mood disorders and apathy are common after
stroke, affect cognitive test performance (and more fundamentally,
patient participation in research), and may reflect impaired
connectivity. Integrating the results from different cohorts that
investigate these underlying mechanisms and consequences is essential to
understand the full impact of vascular disease on brain function and
progression toward the complete spectrum of cognitive
impairments.</p></sec><sec id="sec3.2.3"><label>3.2.3</label><title>Relevance and mapping to next generation
disease coding, ICD-11</title><p>Accurate and uniformly applied diagnoses are essential
in health care and research. The World Health Organization has the main
responsibility for the global classification systems, a core
constitutional task. ICD-10 was published about 25&#x000a0;years ago. Major
advances in the understanding of diseases have occurred since then,
making ICD-10 outdated in several areas. The revision of ICD-10 into
ICD-11 is currently in its final stage.</p><p>A major change from ICD-10 to ICD-11 is that
cerebrovascular diseases will no longer be split across different
chapters, but will constitute &#x0201c;one single section&#x0201d; in
<italic>Diseases of the Nervous System</italic>. ICD-11 will
also, for the first time, include definitions of all cerebrovascular
diagnostic codes including definitions of transient ischemic attack and
the different main types of stroke. It will also encompass
cerebrovascular diseases not causing acute neurological dysfunction:
<italic>silent cerebral infarcts</italic>, <italic>cerebral
microbleeds</italic>, and <italic>silent white matter
abnormalities associated with vascular disease</italic>. The term
&#x0201c;silent&#x0201d; denotes that these entities have not caused acute neurologic
symptoms (and hence are not &#x0201c;strokes&#x0201d;) but are important for brain
function, affect prognosis, and should not be regarded only as
incidental imaging findings.</p><p>The final ICD-11 classification is expected to be
approved for governmental use by the World Health Assembly for release
in 2018, but the prefinal beta draft is officially available at the
World Health Organization website <xref rid="bib52" ref-type="bibr">[52]</xref>. For several research purposes,
it is recommended that the ICD-11 terminology and definitions be
considered and may be applied already at this stage.</p></sec></sec></sec><sec id="sec4"><label>4</label><title>Discussion</title><p>Our initiative identified more than 90 cohort studies, including
over 660,000 participants, many outside current neurodegeneration data
initiatives, most with consent for data sharing, providing substantial scope for
data mining. We acknowledge that our survey is incomplete. However, we consider
it sufficiently representative to draw important conclusions. The segregation of
stroke and dementia remains prevalent 10 years after the National Institute of
Neurological Disorders and Stroke-Canadian Stroke Network (NINDS-CSN) standards
<xref rid="bib11" ref-type="bibr">[11]</xref>, in spite
of recognition that larger frameworks and better diagnostic criteria for
dementias are urgently needed <xref rid="bib1" ref-type="bibr">[1]</xref>, <xref rid="bib53" ref-type="bibr">[53]</xref>. Even among the survey respondents
(likely &#x0201c;cerebrovascular disease enthusiasts&#x0201d;), there was a large gap between
&#x0201c;stroke&#x0201d; and &#x0201c;dementia,&#x0201d; and sparse overlap with the JPND report <xref rid="bib14" ref-type="bibr">[14]</xref>. Although stroke
clinic&#x02013;based studies and RCTs were trying to collect at least some cognitive
data, the methods for testing cognition in such environments are suboptimal.
Meanwhile, the memory clinic&#x02013;based cohorts collected relatively little
information on vascular disease. Undoubtedly, the role of vascular disease in
neurodegeneration remains under-recognized, and under-funded <xref rid="bib54" ref-type="bibr">[54]</xref>, a situation that can no
longer be justified: vascular risk factor reduction prevents stroke and may also
prevent dementia <xref rid="bib3" ref-type="bibr">[3]</xref>
further evidenced by declining dementia incidence paralleling declining stroke
incidence <xref rid="bib16" ref-type="bibr">[16]</xref>.
Fortunately, perspectives may be evolving. A recent call for new conceptual
formulations of AD and dementia cites the need to account for mixed pathologies
and known risk factors (many of which are also stroke risk factors)
<xref rid="bib55" ref-type="bibr">[55]</xref>.
Furthermore, ICD-11 should help identify all cerebrovascular disease
presentations. Standardized diagnostic workup and data collection would
facilitate studies on diagnosis, prognosis, and treatment of vascular factors in
a memory clinic setting, and similarly, studies of cognition, gait, and balance
in a stroke clinic setting (<xref rid="tbl4" ref-type="table">Table&#x000a0;4</xref>). &#x0201c;Transnosological&#x0201d;
research units, integrating specialists in neurovascular and neurodegenerative
disorders would facilitate a global approach to dementia prevention.</p><p>These survey data provide a framework for addressing
interactions between the two leading causes of cognitive decline and dementia:
vascular disease and neurodegeneration. Epidemiological studies and RCTs are
highly complementary when viewed as large data sets en masse. Observational
studies indicate that the most critical period for elevated blood pressure with
regard to cognitive decline is midlife, whereas blood pressure&#x02013;lowering trials
mostly included older patients with follow-up periods too short to detect an
effect. Population studies inform hospital-based post-stroke dementia studies
(and vice versa), often have repeated measures gathered over many years,
enabling the impact of cumulative exposures, and of exposure during specific
ages, to be explored. Important early life information is present in these
studies, for example, birth weight, childhood cognition, socioeconomic data, for
subjects now aged 50 to 70 years, enabling assessment of early life factors on
cerebrovascular disease and dementia risk. Capturing information on both
vascular and neurodegenerative disease from mixed sources improves
generalizability (e.g., RUN DMC; FUTURE; Lund Stroke Registry, <xref rid="appsec2" ref-type="sec">Supplementary Table&#x000a0;1</xref>).
Combining studies that focus on populations in different epidemiological
&#x0201c;windows&#x0201d; relative to the expression of disease enhances mechanisms' discovery
and can relate systemic disease risk (obesity, metabolic, and cardiovascular
disease) to cerebrovascular disease and dementia. Cohort meta-analyses would
help clarify long-term event rates, their prediction, risk factors, and
variation between populations and improve design of RCTs. Existing studies may
provide well-phenotyped &#x0201c;trial ready&#x0201d; subjects with prospective consent for
future research. The challenges involved in harmonization and analysis of large,
diverse data sets are substantial (<xref rid="tbl4" ref-type="table">Table&#x000a0;4</xref>), but methods to overcome this are ongoing
<xref rid="bib56" ref-type="bibr">[56]</xref>, and the
potential rewards are huge. Work already ongoing as a result of this initiative
is listed in <xref rid="appsec2" ref-type="sec">Supplementary
Table&#x000a0;2</xref>.</p><p>Agreeing on a unified cognitive assessment, which can be applied
easily in cerebrovascular disease, is sensitive to relevant domains and relevant
to patients, could have as much impact on identifying treatment to prevent VCI
as the Rankin Scale <xref rid="bib57" ref-type="bibr">[57]</xref> has had on finding acute stroke treatments: without the
common language for functional outcome provided by the Rankin scale, it is
arguable that stroke units, thrombolysis, hemicraniectomy, and thrombectomy
would not have become guideline acute stroke interventions in as little as
20&#x000a0;years. Currently, most stroke RCTs, with few exceptions <xref rid="bib58" ref-type="bibr">[58]</xref>, do not assess cognition.
The evaluation of cognition in stroke patients is complex, difficult, with no
&#x0201c;best cognitive test&#x0201d;. The 2006 collaborative consensus <xref rid="bib11" ref-type="bibr">[11]</xref> proposed three cognitive
protocols with different lengths, one being a brief test for use in large
observational studies and RCTs. Pragmatic, rapid, validated, tools sensitive to
cognitive domains affected by vascular disease early on, are required, like the
MoCA <xref rid="bib59" ref-type="bibr">[59]</xref>. Online
cognitive tests, for example, the UK Biobank Cognitive Testing Enhancement, are
too complex for many stroke patients. In any case, a stepwise approach is needed
to assess vascular effects on neurodegeneration (<xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>). Simple, sensitive, cognitive
scales for use in telephone interviews, validated in patients with
cerebrovascular disease, are needed (<xref rid="tbl4" ref-type="table">Table&#x000a0;4</xref>) <xref rid="bib60" ref-type="bibr">[60]</xref>.</p><p>Several large national initiatives will address dementia
prevention in line with the 2013 G8 Dementia Summit. These draw largely on
healthy or presymptomatic disease populations and offer new opportunities for
systematic, prospective evaluations of people at scale, and often long-term
sample biobanking, genetics, and imaging, enabling some powerful study designs.
These include the Rhineland study (Germany, DZNE, n&#x000a0;=&#x000a0;40,000), the Canadian
Longitudinal Study on Aging (50,000 individuals), the Canadian Alliance for
Healthy Hearts and Minds and Prospective Urban Rural Epidemiological MIND
(PURE-MIND, 11,200 persons), and the UK Biobank <xref rid="bib61" ref-type="bibr">[61]</xref> (500,000 people aged 40&#x02013;70, 100,000
with detailed imaging). These long-term initiatives are complemented by several
national and regional efforts to establish disease-based cohorts, for example,
the Canadian Consortium on Neurodegeneration in Aging (1400 persons; AD, mixed
dementia, MCI, and VCI), or to combine existing cohorts, for example, the DPUK
<xref rid="bib62" ref-type="bibr">[62]</xref>, (29 UK
community cohorts), Cohort Studies of Memory in an International Consortium
(COSMIC) <xref rid="bib18" ref-type="bibr">[18]</xref>,
Virtual International Stroke Trials Archive (VISTA) Cognition <xref rid="bib22" ref-type="bibr">[22]</xref>, and STROKOG
<xref rid="bib23" ref-type="bibr">[23]</xref>. Other
regions should be encouraged and are creating large repositories of data&#x02014;Asia
Pacific Region, Central and America <xref rid="bib63" ref-type="bibr">[63]</xref>, Russia, Africa <xref rid="bib64" ref-type="bibr">[64]</xref>, and Australasia <xref rid="bib18" ref-type="bibr">[18]</xref>.</p><p>Governments, funders, and the public recognize the importance of
sharing publicly funded data. Data from combined analyses of cohorts would
provide larger samples, more robust data on individual cognitive and physical
outcomes, and the interplay between brain and body to maintain healthy, active
populations into old age. The 2015 World Stroke Proclamation on preventable
dementias <xref rid="bib1" ref-type="bibr">[1]</xref> has
been endorsed by several international Alzheimer's, neurological, psychiatric,
and heart associations. Funding for cerebrovascular disease research should more
closely match that spent on dementia or cardiac disease <xref rid="bib54" ref-type="bibr">[54]</xref>. Researchers should work
together to operationalize assessment of vascular effects on neurodegeneration;
stroke should move from &#x0201c;stroke-related&#x0201d; to &#x0201c;anything vascular related including
cognition or other effects&#x0201d; <xref rid="bib52" ref-type="bibr">[52]</xref>; and dementia should move from AD to &#x0201c;any disorder,
arising in or outside the brain, that progressively diminishes cognitive
function&#x0201d;.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Hachinski</surname><given-names>V.</given-names></name></person-group><article-title>Stroke and potentially preventable dementias
proclamation: updated World Stroke Day
Proclamation</article-title><source>Stroke</source><volume>46</volume><year>2015</year><fpage>3039</fpage><lpage>3040</lpage><pub-id pub-id-type="pmid">26504189</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>J.T.</given-names></name><name><surname>Thomas</surname><given-names>A.</given-names></name></person-group><article-title>Vascular dementia</article-title><source>Lancet</source><volume>386</volume><year>2015</year><fpage>1698</fpage><lpage>1706</lpage><pub-id pub-id-type="pmid">26595643</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Ngandu</surname><given-names>T.</given-names></name><name><surname>Lehtisalo</surname><given-names>J.</given-names></name><name><surname>Solomon</surname><given-names>A.</given-names></name><name><surname>Levalahti</surname><given-names>E.</given-names></name><name><surname>Ahtiluoto</surname><given-names>S.</given-names></name><name><surname>Antikainen</surname><given-names>R.</given-names></name></person-group><article-title>A 2 year multidomain intervention of diet, exercise,
cognitive training, and vascular risk monitoring versus control
to prevent cognitive decline in at-risk elderly people (FINGER):
a randomised controlled trial</article-title><source>Lancet</source><volume>385</volume><year>2015</year><fpage>2255</fpage><lpage>2263</lpage><pub-id pub-id-type="pmid">25771249</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Tatemichi</surname><given-names>T.K.</given-names></name><name><surname>Foulkes</surname><given-names>M.A.</given-names></name><name><surname>Mohr</surname><given-names>J.P.</given-names></name><name><surname>Hewitt</surname><given-names>J.R.</given-names></name><name><surname>Hier</surname><given-names>D.B.</given-names></name><name><surname>Price</surname><given-names>T.R.</given-names></name></person-group><article-title>Dementia in stroke survivors in the Stroke Data Bank
cohort. Prevalence, incidence, risk factors, and computed
tomographic findings</article-title><source>Stroke</source><volume>21</volume><year>1990</year><fpage>858</fpage><lpage>866</lpage><pub-id pub-id-type="pmid">2349588</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Pendlebury</surname><given-names>S.T.</given-names></name><name><surname>Rothwell</surname><given-names>P.M.</given-names></name></person-group><article-title>Prevalence, incidence, and factors associated with
pre-stroke and post-stroke dementia: a systematic review and
meta-analysis</article-title><source>Lancet Neurol</source><volume>8</volume><year>2009</year><fpage>1006</fpage><lpage>1018</lpage><pub-id pub-id-type="pmid">19782001</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Hachinski</surname><given-names>V.</given-names></name></person-group><article-title>Vascular dementia: a radical
redefinition</article-title><source>Dementia</source><volume>5</volume><year>1994</year><fpage>130</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">8087166</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Pantoni</surname><given-names>L.</given-names></name></person-group><article-title>Cerebral small vessel disease: from pathogenesis and
clinical characteristics to therapeutic
challenges</article-title><source>Lancet Neurol</source><volume>9</volume><year>2010</year><fpage>689</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">20610345</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Baezner</surname><given-names>H.</given-names></name><name><surname>Blahak</surname><given-names>C.</given-names></name><name><surname>Poggesi</surname><given-names>A.</given-names></name><name><surname>Pantoni</surname><given-names>L.</given-names></name><name><surname>Inzitari</surname><given-names>D.</given-names></name><name><surname>Chabriat</surname><given-names>H.</given-names></name></person-group><article-title>Association of gait and balance disorders with
age-related white matter changes: the LADIS study</article-title><source>Neurology</source><volume>70</volume><year>2008</year><fpage>935</fpage><lpage>942</lpage><pub-id pub-id-type="pmid">18347315</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>H.</given-names></name><name><surname>Cerchiai</surname><given-names>N.</given-names></name><name><surname>Mancuso</surname><given-names>M.</given-names></name><name><surname>Casani</surname><given-names>A.P.</given-names></name><name><surname>Bronstein</surname><given-names>A.M.</given-names></name></person-group><article-title>Are white matter abnormalities associated with
&#x0201c;unexplained dizziness&#x0201d;?</article-title><source>J Neurol Sci</source><volume>358</volume><year>2015</year><fpage>428</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">26412160</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Hachinski</surname><given-names>V.</given-names></name></person-group><article-title>World Stroke Day 2008: &#x0201c;Little strokes, big
trouble&#x0201d;</article-title><source>Stroke</source><volume>39</volume><year>2008</year><fpage>2407</fpage><lpage>2420</lpage><pub-id pub-id-type="pmid">18723419</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Hachinski</surname><given-names>V.</given-names></name><name><surname>Iadecola</surname><given-names>C.</given-names></name><name><surname>Petersen</surname><given-names>R.C.</given-names></name><name><surname>Breteler</surname><given-names>M.M.</given-names></name><name><surname>Nyenhuis</surname><given-names>D.L.</given-names></name><name><surname>Black</surname><given-names>S.E.</given-names></name></person-group><article-title>National Institute of Neurological Disorders and
Stroke-Canadian Stroke Network vascular cognitive impairment
harmonization standards</article-title><source>Stroke</source><volume>37</volume><year>2006</year><fpage>2220</fpage><lpage>2241</lpage><pub-id pub-id-type="pmid">16917086</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Snyder</surname><given-names>H.M.</given-names></name><name><surname>Corriveau</surname><given-names>R.A.</given-names></name><name><surname>Craft</surname><given-names>S.</given-names></name><name><surname>Faber</surname><given-names>J.E.</given-names></name><name><surname>Greenberg</surname><given-names>S.M.</given-names></name><name><surname>Knopman</surname><given-names>D.</given-names></name></person-group><article-title>Vascular contributions to cognitive impairment and
dementia including Alzheimer's disease</article-title><source>Alzheimers Dement</source><volume>11</volume><year>2015</year><fpage>710</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">25510382</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Lodder</surname><given-names>J.</given-names></name></person-group><article-title>Poststroke cognition and the fight against the hard
problem: vascular neurologists, enter the arena!</article-title><source>Stroke</source><volume>38</volume><year>2007</year><fpage>7</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17158332</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="book" id="sref14"><person-group person-group-type="author"><collab>JPND Action Group</collab></person-group><chapter-title>Longitudinal cohort studies in
neurodegeneration</chapter-title><year>2013</year><fpage>1</fpage><lpage>92</lpage><comment>Available at:</comment><ext-link ext-link-type="uri" xlink:href="http://www.neurodegenerationresearch.eu/uploads/media/JPNDAGLCS_Final_Report_Oct_2013-version_07_01_14.pdf" id="intref0025">http://www.neurodegenerationresearch.eu/uploads/media/JPNDAGLCS_Final_Report_Oct_2013-version_07_01_14.pdf</ext-link><comment>Accessed January 13, 2016</comment></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Sachdev</surname><given-names>P.</given-names></name><name><surname>Kalaria</surname><given-names>R.</given-names></name><name><surname>O'Brien</surname><given-names>J.</given-names></name><name><surname>Skoog</surname><given-names>I.</given-names></name><name><surname>Alladi</surname><given-names>S.</given-names></name><name><surname>Black</surname><given-names>S.E.</given-names></name></person-group><article-title>Diagnostic criteria for vascular cognitive disorders:
a VASCOG statement</article-title><source>Alzheimer Dis Assoc Disord</source><volume>28</volume><year>2014</year><fpage>206</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">24632990</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Norton</surname><given-names>S.</given-names></name><name><surname>Matthews</surname><given-names>F.E.</given-names></name><name><surname>Barnes</surname><given-names>D.E.</given-names></name><name><surname>Yaffe</surname><given-names>K.</given-names></name><name><surname>Brayne</surname><given-names>C.</given-names></name></person-group><article-title>Potential for primary prevention of Alzheimer's
disease: an analysis of population-based data</article-title><source>Lancet Neurol</source><volume>13</volume><year>2014</year><fpage>788</fpage><lpage>794</lpage><pub-id pub-id-type="pmid">25030513</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><collab>Prospective Studies
Collaboration</collab></person-group><article-title>Age-specific relevance of usual blood pressure to
vascular mortality: a meta-analysis of individual data for one
million adults in 61 prospective studies</article-title><source>Lancet</source><volume>360</volume><year>2002</year><fpage>1903</fpage><lpage>1913</lpage><pub-id pub-id-type="pmid">12493255</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Sachdev</surname><given-names>P.S.</given-names></name><name><surname>Lipnicki</surname><given-names>D.M.</given-names></name><name><surname>Kochan</surname><given-names>N.A.</given-names></name><name><surname>Crawford</surname><given-names>J.D.</given-names></name><name><surname>Rockwood</surname><given-names>K.</given-names></name><name><surname>Xiao</surname><given-names>S.</given-names></name></person-group><article-title>COSMIC (Cohort Studies of Memory in an International
Consortium): an international consortium to identify risk and
protective factors and biomarkers of cognitive ageing and
dementia in diverse ethnic and sociocultural
groups</article-title><source>BMC Neurol</source><volume>13</volume><year>2013</year><fpage>165</fpage><pub-id pub-id-type="pmid">24195705</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Lees</surname><given-names>R.</given-names></name><name><surname>Fearon</surname><given-names>P.</given-names></name><name><surname>Harrison</surname><given-names>J.K.</given-names></name><name><surname>Broomfield</surname><given-names>N.M.</given-names></name><name><surname>Quinn</surname><given-names>T.J.</given-names></name></person-group><article-title>Cognitive and mood assessment in stroke research:
focused review of contemporary studies</article-title><source>Stroke</source><volume>43</volume><year>2012</year><fpage>1678</fpage><lpage>1680</lpage><pub-id pub-id-type="pmid">22535271</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Bath</surname><given-names>P.M.</given-names></name><name><surname>Geeganage</surname><given-names>C.</given-names></name><name><surname>Gray</surname><given-names>L.J.</given-names></name><name><surname>Collier</surname><given-names>T.</given-names></name><name><surname>Pocock</surname><given-names>S.J.</given-names></name></person-group><article-title>Use of ordinal outcomes in vascular prevention trials:
Comparison with binary outcomes in published
trials</article-title><source>Stroke</source><volume>39</volume><year>2008</year><fpage>2817</fpage><lpage>2823</lpage><pub-id pub-id-type="pmid">18669897</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Neyeloff</surname><given-names>J.L.</given-names></name><name><surname>Fuchs</surname><given-names>S.C.</given-names></name><name><surname>Moreira</surname><given-names>L.B.</given-names></name></person-group><article-title>Meta-analyses and Forest plots&#x000a0;using a microsoft excel
spreadsheet: step-by-step guide&#x000a0;focusing on descriptive data
analysis</article-title><source>BMC Res Notes</source><volume>5</volume><year>2012</year><fpage>52</fpage><pub-id pub-id-type="pmid">22264277</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="book" id="sref22"><person-group person-group-type="author"><collab>Virtual International Stroke Trials
Archive</collab></person-group><chapter-title>Virtual International Stroke Trials Archive
(VISTA)&#x02014;Cognition</chapter-title><year>2015</year><comment>Available at:</comment><ext-link ext-link-type="uri" xlink:href="http://www.vista.gla.ac.uk/index.php/vista-cognition" id="intref0030">http://www.vista.gla.ac.uk/index.php/vista-cognition</ext-link><comment>Accessed January 31, 2016</comment></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="book" id="sref23"><person-group person-group-type="author"><collab>Consortium of Studies of Post-Stroke Cognitive
Decline and Dementia</collab></person-group><chapter-title>Consortium of Studies of Post-Stroke Cognitive Decline
and Dementia (STROKOG)</chapter-title><year>2015</year><comment>Available at:</comment><ext-link ext-link-type="uri" xlink:href="https://cheba.unsw.edu.au/group/strokog" id="intref0035">https://cheba.unsw.edu.au/group/strokog</ext-link><comment>Accessed April 1, 2016</comment></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Pendlebury</surname><given-names>S.T.</given-names></name></person-group><article-title>Stroke-related dementia: rates, risk factors and
implications for future research</article-title><source>Maturitas</source><volume>64</volume><year>2009</year><fpage>165</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">19818568</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Makin</surname><given-names>S.</given-names></name><name><surname>Turpin</surname><given-names>S.</given-names></name><name><surname>Dennis</surname><given-names>M.</given-names></name><name><surname>Wardlaw</surname><given-names>J.</given-names></name></person-group><article-title>Cognitive impairment after lacunar stroke: systematic
review and meta-analysis of incidence, prevalence and comparison
with other stroke sub-types</article-title><source>J Neurol Neurosurg Psychiatry</source><volume>84</volume><year>2013</year><fpage>893</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">23457225</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Aalten</surname><given-names>P.</given-names></name><name><surname>Ramakers</surname><given-names>I.</given-names></name><name><surname>Biessels</surname><given-names>G.</given-names></name><name><surname>De Deyn</surname><given-names>P.</given-names></name><name><surname>Koek</surname><given-names>H.L.</given-names></name><name><surname>OldeRikkert</surname><given-names>M.</given-names></name></person-group><article-title>The Dutch Parelsnoer Institute&#x02014;Neurodegenerative
diseases; methods, design and baseline results</article-title><source>BMC Neurol</source><volume>14</volume><year>2014</year><fpage>1060</fpage></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Inzitari</surname><given-names>D.</given-names></name><name><surname>Pracucci</surname><given-names>G.</given-names></name><name><surname>Poggesi</surname><given-names>A.</given-names></name><name><surname>Carlucci</surname><given-names>G.</given-names></name><name><surname>Barkhof</surname><given-names>F.</given-names></name><name><surname>Chabriat</surname><given-names>H.</given-names></name></person-group><article-title>Changes in white matter as determinant of global
functional decline in older independent outpatients: three year
follow-up of LADIS (leukoaraiosis and disability) study
cohort</article-title><source>BMJ</source><volume>339</volume><year>2009</year><fpage>279</fpage><lpage>282</lpage></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>J.</given-names></name><name><surname>Carmichael</surname><given-names>O.T.</given-names></name><name><surname>Leung</surname><given-names>K.K.</given-names></name><name><surname>Schwarz</surname><given-names>C.</given-names></name><name><surname>Ridgway</surname><given-names>G.R.</given-names></name><name><surname>Bartlett</surname><given-names>J.W.</given-names></name></person-group><article-title>Vascular and Alzheimer's disease markers independently
predict brain atrophy rate in Alzheimer's Disease Neuroimaging
Initiative controls</article-title><source>Neurobiol Aging</source><volume>34</volume><year>2013</year><fpage>1996</fpage><lpage>2002</lpage><pub-id pub-id-type="pmid">23522844</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Kandiah</surname><given-names>N.</given-names></name><name><surname>Chander</surname><given-names>R.J.</given-names></name><name><surname>Ng</surname><given-names>A.</given-names></name><name><surname>Wen</surname><given-names>M.C.</given-names></name><name><surname>Cenina</surname><given-names>A.R.</given-names></name><name><surname>Assam</surname><given-names>P.N.</given-names></name></person-group><article-title>Association between white matter hyperintensity and
medial temporal atrophy at various stages of Alzheimer's
disease</article-title><source>Eur J Neurol</source><volume>22</volume><year>2015</year><fpage>150</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">25142829</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Thoonsen</surname><given-names>H.</given-names></name><name><surname>Richard</surname><given-names>E.</given-names></name><name><surname>Bentham</surname><given-names>P.</given-names></name><name><surname>Gray</surname><given-names>R.</given-names></name><name><surname>van Geloven</surname><given-names>N.</given-names></name><name><surname>De Haan</surname><given-names>R.J.</given-names></name></person-group><article-title>Aspirin in Alzheimer's disease: increased risk of
intracerebral hemorrhage: cause for concern?</article-title><source>Stroke</source><volume>41</volume><year>2010</year><fpage>2690</fpage><lpage>2692</lpage><pub-id pub-id-type="pmid">20930165</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Snijders</surname><given-names>A.H.</given-names></name><name><surname>van de Warrenburg</surname><given-names>B.P.</given-names></name><name><surname>Giladi</surname><given-names>N.</given-names></name><name><surname>Bloem</surname><given-names>B.R.</given-names></name></person-group><article-title>Neurological gait disorders in elderly people:
clinical approach and classification</article-title><source>Lancet Neurol</source><volume>6</volume><year>2007</year><fpage>63</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">17166803</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Verghese</surname><given-names>J.</given-names></name><name><surname>LeValley</surname><given-names>A.</given-names></name><name><surname>Hall</surname><given-names>C.B.</given-names></name><name><surname>Katz</surname><given-names>M.J.</given-names></name><name><surname>Ambrose</surname><given-names>A.F.</given-names></name><name><surname>Lipton</surname><given-names>R.B.</given-names></name></person-group><article-title>Epidemiology of gait disorders in community-residing
older adults</article-title><source>J Am Geriatr Soc</source><volume>54</volume><year>2006</year><fpage>255</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">16460376</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Mahlknecht</surname><given-names>P.</given-names></name><name><surname>Kiechl</surname><given-names>S.</given-names></name><name><surname>Bloem</surname><given-names>B.R.</given-names></name><name><surname>Willeit</surname><given-names>J.</given-names></name><name><surname>Scherfler</surname><given-names>C.</given-names></name><name><surname>Gasperi</surname><given-names>A.</given-names></name></person-group><article-title>Prevalence and burden of gait disorders in elderly men
and women aged 60-97 years: a population-based
study</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><fpage>e69627</fpage><pub-id pub-id-type="pmid">23894511</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Callisaya</surname><given-names>M.L.</given-names></name><name><surname>Beare</surname><given-names>R.</given-names></name><name><surname>Phan</surname><given-names>T.</given-names></name><name><surname>Blizzard</surname><given-names>L.</given-names></name><name><surname>Thrift</surname><given-names>A.G.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Progression of white matter hyperintensities of
presumed vascular origin increases the risk of falls in older
people</article-title><source>J Gerontol A Biol Sci Med Sci</source><volume>70</volume><year>2015</year><fpage>360</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">25199911</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>D.A.</given-names></name><name><surname>Beckett</surname><given-names>L.A.</given-names></name><name><surname>Murray</surname><given-names>A.M.</given-names></name><name><surname>Shannon</surname><given-names>K.M.</given-names></name><name><surname>Goetz</surname><given-names>C.G.</given-names></name><name><surname>Pilgrim</surname><given-names>D.M.</given-names></name></person-group><article-title>Prevalence of parkinsonian signs and associated
mortality in a community population of older
people</article-title><source>N Engl J Med</source><volume>334</volume><year>1996</year><fpage>71</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">8531961</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Buchman</surname><given-names>A.S.</given-names></name><name><surname>Leurgans</surname><given-names>S.E.</given-names></name><name><surname>Nag</surname><given-names>S.</given-names></name><name><surname>Bennett</surname><given-names>D.A.</given-names></name><name><surname>Schneider</surname><given-names>J.A.</given-names></name></person-group><article-title>Cerebrovascular disease pathology and parkinsonian
signs in old age</article-title><source>Stroke</source><volume>42</volume><year>2011</year><fpage>3183</fpage><lpage>3189</lpage><pub-id pub-id-type="pmid">21885844</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>de Laat</surname><given-names>K.F.</given-names></name><name><surname>van Norden</surname><given-names>A.G.</given-names></name><name><surname>Gons</surname><given-names>R.A.</given-names></name><name><surname>van Uden</surname><given-names>I.W.</given-names></name><name><surname>Zwiers</surname><given-names>M.P.</given-names></name><name><surname>Bloem</surname><given-names>B.R.</given-names></name></person-group><article-title>Cerebral white matter lesions and lacunar infarcts
contribute to the presence of mild parkinsonian
signs</article-title><source>Stroke</source><volume>43</volume><year>2012</year><fpage>2574</fpage><lpage>2579</lpage><pub-id pub-id-type="pmid">22858727</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Okroglic</surname><given-names>S.</given-names></name><name><surname>Widmann</surname><given-names>C.N.</given-names></name><name><surname>Urbach</surname><given-names>H.</given-names></name><name><surname>Scheltens</surname><given-names>P.</given-names></name><name><surname>Heneka</surname><given-names>M.T.</given-names></name></person-group><article-title>Clinical symptoms and risk factors in cerebral
microangiopathy patients</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><fpage>e53455</fpage><pub-id pub-id-type="pmid">23393549</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Pantoni</surname><given-names>L.</given-names></name><name><surname>Garcia</surname><given-names>J.H.</given-names></name></person-group><article-title>The significance of cerebral white matter
abnormalities 100 years after Binswanger's report</article-title><source>Stroke</source><volume>26</volume><year>1995</year><fpage>1293</fpage><lpage>1301</lpage><pub-id pub-id-type="pmid">7604429</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Pendlebury</surname><given-names>S.T.</given-names></name><name><surname>Chen</surname><given-names>P.J.</given-names></name><name><surname>Welch</surname><given-names>S.J.</given-names></name><name><surname>Cuthbertson</surname><given-names>F.C.</given-names></name><name><surname>Wharton</surname><given-names>R.M.</given-names></name><name><surname>Mehta</surname><given-names>Z.</given-names></name></person-group><article-title>Methodological factors in determining risk of dementia
after transient ischemic attack and stroke: (II) effect of
attrition on follow-up</article-title><source>Stroke</source><volume>46</volume><year>2015</year><fpage>1494</fpage><lpage>1500</lpage><pub-id pub-id-type="pmid">25953366</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Vermeer</surname><given-names>S.E.</given-names></name><name><surname>Longstreth</surname><given-names>W.T.</given-names><suffix>Jr.</suffix></name><name><surname>Koudstaal</surname><given-names>P.J.</given-names></name></person-group><article-title>Silent brain infarcts: a systematic
review</article-title><source>Lancet Neurol</source><volume>6</volume><year>2007</year><fpage>611</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">17582361</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Debette</surname><given-names>S.</given-names></name><name><surname>Markus</surname><given-names>H.S.</given-names></name></person-group><article-title>The clinical importance of white matter
hyperintensities on brain magnetic resonance imaging: systematic
review and meta-analysis</article-title><source>BMJ</source><volume>341</volume><year>2010</year><fpage>c3666</fpage><pub-id pub-id-type="pmid">20660506</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>de Groot</surname><given-names>J.C.</given-names></name><name><surname>de Leeuw</surname><given-names>F.E.</given-names></name><name><surname>Oudkerk</surname><given-names>M.</given-names></name><name><surname>van Gijn</surname><given-names>J.</given-names></name><name><surname>Hofman</surname><given-names>A.</given-names></name><name><surname>Jolles</surname><given-names>J.</given-names></name></person-group><article-title>Cerebral white matter lesions and cognitive function:
the Rotterdam Scan Study</article-title><source>Ann Neurol</source><volume>47</volume><year>2000</year><fpage>145</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">10665484</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Tuladhar</surname><given-names>A.M.</given-names></name><name><surname>Reid</surname><given-names>A.T.</given-names></name><name><surname>Shumskaya</surname><given-names>E.</given-names></name><name><surname>de Laat</surname><given-names>K.F.</given-names></name><name><surname>van Norden</surname><given-names>A.G.</given-names></name><name><surname>van Dijk</surname><given-names>E.J.</given-names></name></person-group><article-title>Relationship between white matter hyperintensities,
cortical thickness, and cognition</article-title><source>Stroke</source><volume>46</volume><year>2015</year><fpage>425</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">25572411</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Duering</surname><given-names>M.</given-names></name><name><surname>Righart</surname><given-names>R.</given-names></name><name><surname>Csanadi</surname><given-names>E.</given-names></name><name><surname>Jouvent</surname><given-names>E.</given-names></name><name><surname>Herve</surname><given-names>D.</given-names></name><name><surname>Chabriat</surname><given-names>H.</given-names></name></person-group><article-title>Incident subcortical infarcts induce focal thinning in
connected cortical regions</article-title><source>Neurology</source><volume>79</volume><year>2012</year><fpage>2025</fpage><lpage>2028</lpage><pub-id pub-id-type="pmid">23054230</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Duering</surname><given-names>M.</given-names></name><name><surname>Righart</surname><given-names>R.</given-names></name><name><surname>Wollenweber</surname><given-names>F.A.</given-names></name><name><surname>Zietemann</surname><given-names>V.</given-names></name><name><surname>Gesierich</surname><given-names>B.</given-names></name><name><surname>Dichgans</surname><given-names>M.</given-names></name></person-group><article-title>Acute infarcts cause focal thinning in remote cortex
via degeneration of connecting fiber tracts</article-title><source>Neurology</source><volume>84</volume><year>2015</year><fpage>1685</fpage><lpage>1692</lpage><pub-id pub-id-type="pmid">25809303</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>A.J.</given-names></name><name><surname>Chung</surname><given-names>A.W.</given-names></name><name><surname>Morris</surname><given-names>R.G.</given-names></name><name><surname>Markus</surname><given-names>H.S.</given-names></name><name><surname>Barrick</surname><given-names>T.R.</given-names></name></person-group><article-title>Structural network efficiency is associated with
cognitive impairment in small-vessel disease</article-title><source>Neurology</source><volume>83</volume><year>2014</year><fpage>304</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">24951477</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Tuladhar</surname><given-names>A.M.</given-names></name><name><surname>van Uden</surname><given-names>I.W.</given-names></name><name><surname>Rutten-Jacobs</surname><given-names>L.C.</given-names></name><name><surname>Lawrence</surname><given-names>A.</given-names></name><name><surname>van der Holst</surname><given-names>H.</given-names></name><name><surname>van Norden</surname><given-names>A.</given-names></name></person-group><article-title>Structural network efficiency predicts conversion to
dementia</article-title><source>Neurology</source><volume>86</volume><year>2016</year><fpage>1112</fpage><lpage>1119</lpage><pub-id pub-id-type="pmid">26888983</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>R.Y.</given-names></name><name><surname>Jagust</surname><given-names>W.J.</given-names></name></person-group><article-title>Vascular burden and Alzheimer disease pathologic
progression</article-title><source>Neurology</source><volume>79</volume><year>2012</year><fpage>1349</fpage><lpage>1355</lpage><pub-id pub-id-type="pmid">22972646</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Haight</surname><given-names>T.J.</given-names></name><name><surname>Landau</surname><given-names>S.M.</given-names></name><name><surname>Carmichael</surname><given-names>O.</given-names></name><name><surname>Schwarz</surname><given-names>C.</given-names></name><name><surname>DeCarli</surname><given-names>C.</given-names></name><name><surname>Jagust</surname><given-names>W.J.</given-names></name></person-group><article-title>Dissociable effects of Alzheimer disease and white
matter hyperintensities on brain metabolism</article-title><source>JAMA Neurol</source><volume>70</volume><year>2013</year><fpage>1039</fpage><lpage>1045</lpage><pub-id pub-id-type="pmid">23779022</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Tullberg</surname><given-names>M.</given-names></name><name><surname>Fletcher</surname><given-names>E.</given-names></name><name><surname>DeCarli</surname><given-names>C.</given-names></name><name><surname>Mungas</surname><given-names>D.</given-names></name><name><surname>Reed</surname><given-names>B.R.</given-names></name><name><surname>Harvey</surname><given-names>D.J.</given-names></name></person-group><article-title>White matter lesions impair frontal lobe function
regardless of their location</article-title><source>Neurology</source><volume>63</volume><year>2004</year><fpage>246</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">15277616</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="book" id="sref52"><person-group person-group-type="author"><collab>World Health Organisation</collab></person-group><chapter-title>ICD-11 Beta Draft</chapter-title><year>2015</year><comment>Available at:</comment><ext-link ext-link-type="uri" xlink:href="http://apps.who.int/classifications/icd11/browse/f/en" id="intref0040">http://apps.who.int/classifications/icd11/browse/f/en</ext-link><comment>Accessed January16, 2016</comment></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Hachinski</surname><given-names>V.</given-names></name></person-group><article-title>Stroke and vascular cognitive impairment: a
transdisciplinary, translational and transactional
approach</article-title><source>Stroke</source><volume>38</volume><year>2007</year><fpage>1396</fpage><lpage>1403</lpage><pub-id pub-id-type="pmid">17347469</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="book" id="sref54"><person-group person-group-type="author"><collab>Medical Research Council</collab></person-group><chapter-title>MRC workshop on neurovascular ageing in health and
disease: interplay of the CNS and vascular system</chapter-title><year>2015</year><publisher-name>Medical Research Council</publisher-name><publisher-loc>London, UK</publisher-loc><fpage>1</fpage><lpage>34</lpage></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Khachaturian</surname><given-names>Z.S.</given-names></name><name><surname>Mesulam</surname><given-names>M.M.</given-names></name><name><surname>Khachaturian</surname><given-names>A.S.</given-names></name><name><surname>Mohs</surname><given-names>R.C.</given-names></name></person-group><article-title>The special topics section of Alzheimer's &#x00026;
Dementia</article-title><source>Alzheimers Dement</source><volume>11</volume><year>2015</year><fpage>1261</fpage><lpage>1264</lpage><pub-id pub-id-type="pmid">26589667</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="book" id="sref56"><person-group person-group-type="author"><name><surname>Mathers</surname><given-names>J.C.</given-names></name><name><surname>Deary</surname><given-names>I.J.</given-names></name><name><surname>Kuh</surname><given-names>D.</given-names></name><name><surname>Lord</surname><given-names>J.M.</given-names></name><name><surname>Khaw</surname><given-names>K.T.</given-names></name><name><surname>Lara</surname><given-names>J.</given-names></name></person-group><chapter-title>Guidelines for biomarkers of healthy
ageing</chapter-title><year>2015</year><fpage>1</fpage><lpage>93</lpage><comment>Available at:</comment><ext-link ext-link-type="uri" xlink:href="https://www.mrc.ac.uk/documents/pdf/biomarkers-of-healthy-ageing/" id="intref0045">https://www.mrc.ac.uk/documents/pdf/biomarkers-of-healthy-ageing/</ext-link><comment>Accessed January 15, 2016</comment></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Rankin</surname><given-names>J.</given-names></name></person-group><article-title>Cerebral vascular accidents in patients over the age
of 60. II. Prognosis</article-title><source>Scott Med J</source><volume>2</volume><year>1957</year><fpage>200</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">13432835</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>L.A.</given-names></name><name><surname>McClure</surname><given-names>L.A.</given-names></name><name><surname>Anderson</surname><given-names>D.C.</given-names></name><name><surname>Jacova</surname><given-names>C.</given-names></name><name><surname>Sharma</surname><given-names>M.</given-names></name><name><surname>Hart</surname><given-names>R.G.</given-names></name></person-group><article-title>Effects of long-term blood pressure lowering and dual
antiplatelet treatment on cognitive function in patients with
recent lacunar stroke: a secondary analysis from the SPS3
randomised trial</article-title><source>Lancet Neurol</source><volume>13</volume><year>2014</year><fpage>1177</fpage><lpage>1185</lpage><pub-id pub-id-type="pmid">25453457</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Chiti</surname><given-names>G.</given-names></name><name><surname>Pantoni</surname><given-names>L.</given-names></name></person-group><article-title>Use of Montreal Cognitive Assessment in patients with
stroke</article-title><source>Stroke</source><volume>45</volume><year>2014</year><fpage>3135</fpage><lpage>3140</lpage><pub-id pub-id-type="pmid">25116881</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Castanho</surname><given-names>T.C.</given-names></name><name><surname>Amorim</surname><given-names>L.</given-names></name><name><surname>Zihl</surname><given-names>J.</given-names></name><name><surname>Palha</surname><given-names>J.A.</given-names></name><name><surname>Sousa</surname><given-names>N.</given-names></name><name><surname>Santos</surname><given-names>N.C.</given-names></name></person-group><article-title>Telephone-based screening tools for mild cognitive
impairment and dementia in aging studies: a review of validated
instruments</article-title><source>Front Aging Neurosci</source><volume>6</volume><year>2014</year><fpage>16</fpage><pub-id pub-id-type="pmid">24611046</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Sudlow</surname><given-names>C.</given-names></name><name><surname>Gallacher</surname><given-names>J.</given-names></name><name><surname>Allen</surname><given-names>N.</given-names></name><name><surname>Beral</surname><given-names>V.</given-names></name><name><surname>Burton</surname><given-names>P.</given-names></name><name><surname>Danesh</surname><given-names>J.</given-names></name></person-group><article-title>UK biobank: an open access resource for identifying
the causes of a wide range of complex diseases of middle and old
age</article-title><source>PLoS Med</source><volume>12</volume><year>2015</year><fpage>e1001779</fpage><pub-id pub-id-type="pmid">25826379</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="book" id="sref62"><person-group person-group-type="author"><collab>Dementias Platforms UK and Medical Research
Council</collab></person-group><chapter-title>Dementias Platforms UK (DPUK)</chapter-title><year>2015</year><comment>Available at:</comment><ext-link ext-link-type="uri" xlink:href="http://www.dementiasplatform.uk/" id="intref0050">http://www.dementiasplatform.uk/</ext-link><comment>Accessed January 31, 2016</comment></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Sposato</surname><given-names>L.A.</given-names></name><name><surname>Coppola</surname><given-names>M.L.</given-names></name><name><surname>Altamirano</surname><given-names>J.</given-names></name><name><surname>Borrego Guerrero</surname><given-names>B.</given-names></name><name><surname>Casanova</surname><given-names>J.</given-names></name><name><surname>De Martino</surname><given-names>M.</given-names></name></person-group><article-title>Program for the epidemiological evaluation of stroke
in Tandil, Argentina (PREVISTA) study: rationale and
design</article-title><source>Int J Stroke</source><volume>8</volume><year>2013</year><fpage>591</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">24024917</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Akinyemi</surname><given-names>R.O.</given-names></name><name><surname>Allan</surname><given-names>L.</given-names></name><name><surname>Owolabi</surname><given-names>M.O.</given-names></name><name><surname>Akinyemi</surname><given-names>J.O.</given-names></name><name><surname>Ogbole</surname><given-names>G.</given-names></name><name><surname>Ajani</surname><given-names>A.</given-names></name></person-group><article-title>Profile and determinants of vascular cognitive
impairment in African stroke survivors: the CogFAST Nigeria
Study</article-title><source>J Neurol Sci</source><volume>346</volume><year>2014</year><fpage>241</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">25238666</pub-id></element-citation></ref></ref-list><sec id="appsec1"><label>Appendix</label><title>Authors</title><p>Study co-ordination, analysis and paper preparation: Martin
Dichgans (1, Institute for Stroke and Dementia Research (ISD), Klinikum der
Universit&#x000e4;t M&#x000fc;nchen, Ludwig-Maximilians-University LMU, Munich Germany; 2,
German Centre for Neurodegenerative Diseases (DZNE, Munich), Munich Germany; and
3, Munich Cluster for Systems Neurology (SyNergy), Munich, Germany); Joanna
Wardlaw (Centre for Clinical Brain Sciences, University of Edinburgh, UK); Eric
Smith (University of Calgary, Canada); Vera Zietemann (Institute for Stroke and
Dementia Research (ISD), Klinikum der Universit&#x000e4;t M&#x000fc;nchen,
Ludwig-Maximilians-University, Munich, Germany); Sudha Seshadri (Boston
University, USA); Perminder Sachdev (University of New South Wales, Australia);
Geert Jan Biessels (UMC Utrecht, Netherlands); Franz Fazekas (Medical University
of Graz, Austria); Oscar Benavente (University of British Columbia, Canada);
Leonardo Pantoni (Azienda Ospedaliero Universitaria Careggi, Florence, Italy);
Frank-Erik De Leeuw (Radboud University Medical Center Nijmegen, Netherlands);
Bo Norrving (Lund University, Sweden); Paul Matthews (Imperial College, London,
UK); Christopher Chen (National University of Singapore); Vincent Mok (The
Chinese University of Hong Kong, China); Marco D&#x000fc;ring (Institute for Stroke and
Dementia Research (ISD), Klinikum der Universit&#x000e4;t M&#x000fc;nchen,
Ludwig-Maximilians-University, Munich, Germany); Will Whiteley (University of
Edinburgh, UK); Kirsten Shuler (University of Edinburgh, Edinburgh,
UK).</p><p>Participants in working groups, survey, interpretation: Alvaro
Alonso (University of Minnesota, USA); Sandra E Black (Sunnybrook Health
Sciences Centre, University of Toronto, Canada); Carol Brayne (University of
Cambridge, UK); Hugues Chabriat (Univ Paris Diderot, and DHU NeuroVasc, both at
Sorbonne Paris Cit&#x000e9;, UMR-S 1161 INSERM, F-75205 Paris; Hopital Lariboisiere,
Dept of Neurology, F-75475 Paris, France); Charlotte Cordonnier (University
Lille, Inserm, CHU, U1171 Degenerative and Cascular Cognitive Disorders,
F-59000, Lille, France); Fergus Doubal (University of Edinburgh, Edinburgh, UK);
Emrah Duzel (DZNE Magdeburg, Germany); Michael Ewers (Institute for Stroke and
Dementia Research (ISD), Klinikum der Universit&#x000e4;t M&#x000fc;nchen,
Ludwig-Maximilians-University, Munich, Germany); Richard Frayne (University of
Calgary, Canada); Vladimir Hachinski (Rush University Medical Center, London,
Ontario, Canada); Mohammad Arfan Ikram (Erasmus MC, Rotterdam, The Netherlands);
Frank Jessen (University of Cologne, Germany); Eric Jouvent (Univ Paris Diderot,
and DHU NeuroVasc, both at Sorbonne Paris Cit&#x000e9;, UMR-S 1161 INSERM, F-75205
Paris; Hopital Lariboisiere, Dept of Neurology, F-75475 Paris, France); Jennifer
Linn (University Hospital Dresden, Germany); John O'Brien (University of
Cambridge, UK); Robert van Oostenbrugge (Maastricht UMC, Netherlands); Rainer
Malik (Institute for Stroke and Dementia Research (ISD), Klinikum der
Universit&#x000e4;t M&#x000fc;nchen, Ludwig-Maximilians-University, Munich, Germany); Bernard
Mazoyer (University of Bordeaux, France); Reinhold Schmidt (Medical University
Graz, Austria); Luciano A Sposato (Western University, London, Canada); Blossom
Stephan (Newcastle University, UK); Richard H Swartz (Sunnybrook Health Sciences
Centre, University of Toronto, Toronto, Canada); Meike Vernooij (Erasmus MC,
Rotterdam, The Netherlands); Anand Viswanathan (Massachusetts General Hospital,
Boston, USA); David Werring (UCL Institute of Neurology, London, UK).</p><p>Participants in the survey: Koji Abe (Okayama University
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan);
Louise Allan ((Newcastle University, Newcastle, UK), Francesco Arba (University
of Florence, Italy) on behalf of the VISTA Collaboration*; Hee-Joon Bae (Seoul
National University Bundang Hospital, Republic of Korea (South Korea)); Philip
MW Bath (University of Nottingham, UK); Regis Bordet (University Lille, Inserm,
CHU, U1171 Degenerative and Vascular Cognitive Disorders, F-59000 Lille,
France); Monique Breteler (German Center for Neurodegenerative Diseases (DZNE),
Berlin, Germany); Seong Choi (Inha University Hospital, Incheon, Korea); Ian
Deary (University of Edinburgh, UK); Charles DeCarli (University of California,
USA); Klaus Ebmeier (University of Oxford, Warneford Hospital, Oxford, UK); Lei
Feng (National University of Singapore); Steven M Greenberg (Massachusetts
General Hospital, Boston, USA); Masafumi Ihara (National Cerebral and
Cardiovascular Centre, Suita, Osaka, Japan); Rajesh Kalaria (Newcastle
University, Newcastle, UK); SanYun Kim (Seoul National University Bundang
Hospital, Republic of Korea (South Korea)); Jae-Sung Lim (Dept of Neurology,
Hallym University Sacred Heart Hospital, Anyang, Republic of Korea (South
Korea)); Richard I Lindley (University of Sydney, Australia); Gillian Mead
(University of Edinburgh, UK); Alison Murray (University of Aberdeen, UK); Terry
Quinn (University of Glasgow, UK); Craig Ritchie (University of Edinburgh, UK);
Ralph Sacco (University of Miami, USA); Rustam Al-Shahi Salman (University of
Edinburgh, UK); Nikola Sprigg (University of Nottingham, UK); Cathie Sudlow
(University of Edinburgh, UK); Alan Thomas (Institute of Neuroscience and
Newcastle University Institute for Ageing, Newcastle University, Newcastle, UK);
Martin van Boxtel (Maastricht University, Netherlands); Jeroen van der Grond
(Leiden University Medical Center, Netherlands); Aad van der Lugt (Erasmus MC,
Rotterdam, The Netherlands); Yuan-Han Yang (Kaohsiung Medical University
Hospital, Taiwan).</p><p>*VISTA Prevention Steering Committee: H-C Diener (Chair), S
Davis, G Hankey, KR Lees, B Ovbiagele, C Weir.</p></sec><sec id="appsec2" sec-type="supplementary-material"><title>Supplementary data</title><p><supplementary-material content-type="local-data" id="ec1"><caption><title>Supplementary Material</title></caption><media xlink:href="mmc1.docx"/></supplementary-material><supplementary-material content-type="local-data" id="ec2"><caption><title>Appendix</title></caption><media xlink:href="mmc2.pdf"/></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgments</title><p>The following funders supported the work: <funding-source id="gs1">Joint Programme for Neurodegenerative Disease</funding-source> (JPND)
Research, specifically the <funding-source id="gs2">UK Medical Research
Council</funding-source>, the <funding-source id="gs3">Deutsches Zentrum f&#x000fc;r
Neurodegenerative Erkrankungen</funding-source> (DZNE), and the
<funding-source id="gs4">Canadian Institutes of Health Research</funding-source> (CIHR). The Scottish
Imaging Network, A Platform for Scientific Excellence (SINAPSE) through the Pools
Engagement in Europe (PEER) funding from the <funding-source id="gs5">Scottish Funding
Council</funding-source>. The Therese Pei Fong Chow Research Centre for
Prevention of Dementia (in memory of Donald H K Chow). The authors thank the Siemens
Foundation, Munich, Germany, for providing the workshop venue and catering.
F.-E.D.L. acknowledges VIDI Innovation Grant from ZonMW ref 016.126.351. P.M.M.
acknowledges generous support from the Edmond J Safra Foundation and Lily Safra and
the Imperial College Health Trust BRC. P.M.W.B. is Stroke Association Professor of
Stroke Medicine. C.de.C. acknowledges support from Centre Grant <funding-source id="gs6">NIH</funding-source>
P30 AG 010129. MD, JMW, GJB, RVO
acknowledge EU Horizon 2020 SVDs@Target grant agreement No 666881.</p><p>In the short term, the main source of information about these
cohorts is <xref rid="appsec2" ref-type="sec">Supplementary
Table&#x000a0;1</xref>, while work continues to enable a platform to improve
accessibility and searching for study data.</p><p>Author contributions.</p><p>Obtaining funding: JMW, MD. Project management and administration:
JMW, MD, ES. Design and testing of survey: MD, ES, JMW, KS. Survey distribution: ES,
MD, JMW, KS, CC, VM. Data collection: all authors. Data analysis: VZ, KS, JMW.
Manuscript preparation: JMW, MD, ES, VZ, SS, PS, GJB, FF, LP, FEdeL, BN, PM, MD, WW.
Preparation of figures: MD, FEdeL, VZ, MD, KS. Critical comment and data checking:
all authors. Final approval to submit: all authors.</p></ack><fn-group><fn id="d31e776"><p id="ntpara0015">Declaration of interests: A Alonso, R Al-Shahi Salman, F
Arba, H-J Bae, C Brayne, H Chabriat, C Chen, C Cordonnier, C DeCarli, M Dichgans, M
Duering, F Fazekas, L Feng, S Greenberg, M Ihara, E Jouvent, R Kalaria, S-Y Kim, J-S
Lim, RI Lindley, J Linn, R Malik, B Mazoyer, V Mok, B Norrving, L Pantoni, C
Ritchie, R Sacco, R Schmidt, S Seshadri, L Sposato, N Sprigg, B Stephan, R Swartz, M
van Boxtel, J Van der Grond, R van Oostenbrugge, M Vernooij, D Werring, W Whiteley,
and V Zietemann have no disclosures. P Bath reports grants from UK Medical Research
Council, NIHR Health Technology Assessment, Stroke Association, Alzheimer's Society,
British Heart Foundation, during the conduct of the study. Outside the submitted
work, S Black reports institutional grants from Pfizer, GE Healthcare, Eli Lilly,
Elan/Transition Therapeutics, Roche, Cognoptix, and personal fees from Pfizer, GE
Healthcare, Eli Lilly, Eisai, Boehringer Ingelheim, Novartis. R Bordet reports
grants from French Minister of Health, Fondation Coeur et Art&#x000e8;re, during the conduct
of the study. I Deary reports grants from Age UK, UK Medical Research Council, UK
Biotechnology and Biological Sciences Research Council, during the conduct of the
study. F-E de Leeuw reports grants from VIDI innovational grant (ZonMW), during the
conduct of the study. F Doubal reports grants from JPND (Medical Research Council
and Canadian Institutes of Health Research), The Stroke Association and Garfield
Weston Foundation, during the conduct of the study. KP Ebmeier reports grants from
UK Medical Research Council, The HDH Wills 1965 Charitable Trust, Gordon Edward
Small's Charitable Trust, National Institute of Health Research, Alzheimer Research
UK, and personal fees from Eli Lily, GE, and grants from Various Pharmaceutical
Companies, outside the submitted work. M Ewers received grants from the European
Commission, Alzheimer Forschung Initiative and LMU. R Frayne reports grants from
CIHR, during the conduct of the study; grants from CIHR, outside the submitted work.
J O'Brien reports personal fees from GE Healthcare, TauRx, Cytox, grants and
personal fees from Avid/Lilly, outside the submitted work. T Quinn is a founding
member of VISTA cognition, a not for profit resource that collates individual
patient level data relating to cognition and stroke. P Sachdev reports grants from
NHMRC Program Grant ID 568969, during the conduct of the study. K Shuler reports
grants from JPND (Medical Research Council), grants from Scottish Funding Council
PEER SINAPSE, during the conduct of the study. E Smith reports grants from Canadian
Institutes of Health Research, during the conduct of the study and from the Heart
and Stroke Foundation of Canada, outside the submitted work. A Thomas reports grants
from NIHR BRU in Lewy Body Dementia, during the conduct of the study. A Viswanathan
reports personal fees from Roche Pharmaceuticals, outside the submitted work. JM
Wardlaw reports grants from JPND (Medical Research Council and Canadian Institutes
of Health Research), and Scottish Funding Council PEER SINAPSE, during the conduct
of the study.</p></fn><fn id="appsec3" fn-type="supplementary-material"><p>Supplementary data related to this article can be found at
<ext-link ext-link-type="doi" xlink:href="10.1016/j.jalz.2016.06.004" id="intref0020">http://dx.doi.org/10.1016/j.jalz.2016.06.004</ext-link>.</p></fn></fn-group></back><floats-group><fig id="fig1"><label>Fig.&#x000a0;1</label><caption><p>Approaches to tackling vascular factors in
neurodegenerative disease. The challenge is to integrate the different clinical
presentations when attempting to recognize more completely the interactions
between vascular disease and neurodegeneration and thence improve prevention and
treatment.</p></caption><graphic xlink:href="gr1"/></fig><fig id="fig2"><label>Fig.&#x000a0;2</label><caption><p>Duration of follow-up by study type and available
information. Note some community-based studies have &#x0003e;5&#x000a0;years of
follow-up.</p></caption><graphic xlink:href="gr2"/></fig><fig id="fig3"><label>Fig.&#x000a0;3</label><caption><p>Dynamic effects of small vessel disease on the
brain: (A) Periventricular and deep white matter hyperintensity (WMH; orange)
can increase in size (red), occasionally shrink, and lead to atrophy of white
matter. (B) Acute small subcortical infarcts (dashed black line) may cavitate
and shrink (black area), develop into a WMH (orange) or disappear. Distant
effects (blue) involve thinning of connected cortex and degeneration of
projection fibers.</p></caption><graphic xlink:href="gr3"/></fig><table-wrap id="tbl1" position="float"><label>Table&#x000a0;1</label><caption><p>Summary of types and amount of data available in
cohorts recorded in the survey that were analyzed in detail</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Community-based cohorts</th><th>Hospital-based cohorts from stroke services</th><th>Hospital-based cohorts from memory clinics</th><th>Clinical trials</th><th>All</th></tr></thead><tbody><tr><td colspan="6">Number of studies</td></tr><tr><td>&#x000a0;Total/completed recruitment/completed
follow-up</td><td>28/22/15</td><td>12/8/5</td><td>16/8/4</td><td>12/7/5</td><td>68/45/29</td></tr><tr><td>Current number of patients</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Total/with imaging<xref rid="tbl1fnlowast" ref-type="table-fn">&#x02217;</xref></td><td>583.851/23.388</td><td>4.134/3.529</td><td>19.144/5.982</td><td>20.035/12.050</td><td>627.164/44.949</td></tr><tr><td>Planned sample size</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Total/with imaging data</td><td>&#x0003e;600.000/&#x0003e;150.000</td><td>4.702/4.289</td><td>21.353/8.153</td><td>22.314/12.439</td><td>&#x0223c;655.000/&#x0223c;172.000</td></tr><tr><td>Mean age (y)</td><td>71</td><td>70</td><td>73</td><td>71.6</td><td>72</td></tr><tr><td>Male sex (%)</td><td>46</td><td>56</td><td>51</td><td>58.5</td><td>46</td></tr><tr><td>Number of studies with</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Clinical diagnosis of stroke supported by
neuroimaging</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;MRI/CT/MRI or CT</td><td>6/1/4</td><td>5/4/3</td><td>4/0/2</td><td>3/2/6</td><td>18/7/15</td></tr><tr><td>&#x000a0;Baseline information on risk factors</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Hypertension/diabetes
mellitus/hypercholesterolemia/smoking/medication/education</td><td>26/26/22/26/27/27</td><td>12/12/12/12/12/11</td><td>16/16/16/16/15/16</td><td>10/10/10/9/8/4</td><td>64/64/60/63/62/58</td></tr><tr><td>&#x000a0;Follow-up assessment</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;After months 3/6/12/24/36/48/60</td><td>1/2/6/10/10/5/6</td><td>9/6/9/3/6/3/6</td><td>0/4/14/9/7/1/0</td><td>7/4/5/2/2/0/0</td><td>17/16/34/24/25/9/12</td></tr><tr><td>&#x000a0;Functional outcomes</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;mRS/BI/SIS/EuroQol/SF36/ADL or IADL</td><td>3/2/0/1/2/5</td><td>7/7/1/2/2/2</td><td>4/4/1/3/0/4</td><td>8/3/1/7/1/0</td><td>22/16/3/13/5/11</td></tr><tr><td>&#x000a0;Vascular outcomes</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Stroke/TIA/MI/Vascular death</td><td>17/14/16/15</td><td>10/7/7/8</td><td>14/12/10/9</td><td>9/8/9/7</td><td>50/41/42/39</td></tr><tr><td>&#x000a0;Cognitive outcomes</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;MCI/Dementia/MoCA or
ACE-R/MMSE/TICS/Memory/Executive/Reaction time/Visuospatial</td><td>7/15/4/17/16/18/15/16</td><td>7/9/7/10/8/7/4/7</td><td>8/11/6/12/14/14/10/14</td><td>1/2/1/8/6/4/4/4/4</td><td>23/37/18/47/44/43/33/41</td></tr><tr><td>&#x000a0;Psychiatric outcomes</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Depression/anxiety</td><td>18/12</td><td>9/7</td><td>14/7</td><td>7/0</td><td>48/26</td></tr><tr><td>&#x000a0;Mobility outcomes</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Gait/balance/manual dexterity</td><td>1/0/0</td><td>1/0/0</td><td>1/0/0</td><td>0/0/0</td><td>3/0/0</td></tr><tr><td>&#x000a0;Criteria used for a diagnosis of MCI</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;DSM-V/AHA or ASA/Petersen/NIA-AA/other</td><td>1/1/4/3/2</td><td>2/1/3/0/1</td><td>0/2/2/6/3</td><td>0/0/0/0/6</td><td>3/4/9/9/12</td></tr><tr><td>&#x000a0;Criteria used for a diagnosis of dementia</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;DSM-IV/DSM-V/ICD-10/other</td><td>7/3/3/3</td><td>5/1/1/0</td><td>10/0/0/3</td><td>1/0/0/6</td><td>23/4/4/12</td></tr><tr><td>&#x000a0;Criteria used for diagnosis of vascular CI</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;NINDS-AIREN/AHA or ASA/other</td><td>8/4/2</td><td>1/1/1</td><td>7/4/1</td><td>0/0/0</td><td>16/9/4</td></tr><tr><td>&#x000a0;Criteria used for a diagnosis of AD</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;NIA-AA
clinical/DSM-V/DSM-V/NINCDS-ADRDA/other</td><td>5/5/0/2/6</td><td>1/4/1/0/0</td><td>8/2/1/4/2</td><td>0/0/0/0/0</td><td>14/11/2/6/8</td></tr><tr><td>&#x000a0;Stored sample</td><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;DNA/blood</td><td>26/20</td><td>7/6</td><td>13/14</td><td>3/3</td><td>49/43</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>Abbreviations: ACE-R, revised Addenbrooke's
cognitive examination; AD, Alzheimer's disease; AHA, American Heart Association;
AIREN, Association Internationale pour la Recherch&#x000e9; et l'Enseignement en
Neurosciences; ASA, American Stroke Association; CT, computed tomography; DSM,
Diagnostic and Statistical Manual of Mental Disorders; ICD, International
Classification of Disease; MoCA, Montreal Cognitive Assessment; MCI, mild
cognitive impairment; MI, myocardial infarction; MMSE, mini-mental state
examination; MRI, magnetic resonance imaging; NIA-AA, National Institutes of
Aging&#x02013;Alzheimer's Association; NINDS, National Institute for Neurological
Disorders and Stroke; TIA, transient ischaemic attack; TICS, Telephone Interview
of Cognitive Assessment.</p></fn><fn id="tspara0020"><p>NOTE. For studies not included in detailed analysis
and full details of all studies, see <xref rid="appsec2" ref-type="sec">Supplementary Table&#x000a0;1</xref>.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnlowast"><label>&#x02217;</label><p id="ntpara0010">Number includes UK Biobank of 500,000 recruited,
100,000 expected to have brain and other imaging. For 11 cross-sectional and 17
longitudinal studies not listed in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>, see <xref rid="appsec2" ref-type="sec">Supplementary Material</xref>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table&#x000a0;2</label><caption><p>Summary of 84 observational cohort studies by study
setting</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Setting</th><th>n</th></tr></thead><tbody><tr><td>Observational studies</td><td align="char">84</td></tr><tr><td>&#x000a0;Cross sectional</td><td align="char">11</td></tr><tr><td>&#x000a0;Longitudinal</td><td align="char">73</td></tr><tr><td>Community based</td><td align="char">32</td></tr><tr><td>&#x000a0;Via advertising</td><td align="char">9</td></tr><tr><td>&#x000a0;Population based</td><td align="char">23</td></tr><tr><td>Hospital based for some recruits and community based
for others</td><td align="char">4</td></tr><tr><td>&#x000a0;Stroke or TIA clinic</td><td align="char">1</td></tr><tr><td>&#x000a0;Stroke or TIA clinic and memory clinic</td><td align="char">1</td></tr><tr><td>&#x000a0;Memory clinic and general geriatric clinic</td><td align="char">1</td></tr><tr><td>&#x000a0;Other</td><td align="char">1</td></tr><tr><td>Hospital/clinical based</td><td align="char">37</td></tr><tr><td>&#x000a0;Stroke or TIA clinic</td><td align="char">19</td></tr><tr><td>&#x000a0;Stroke or TIA clinic and memory clinic</td><td align="char">2</td></tr><tr><td>&#x000a0;Stroke or TIA clinic and memory clinic and general
geriatric clinic</td><td align="char">3</td></tr><tr><td>&#x000a0;Stroke or TIA clinic and memory clinic and general
geriatric clinic and any healthy volunteers</td><td align="char">1</td></tr><tr><td>&#x000a0;Stroke or TIA clinic and memory clinic and any
healthy volunteers</td><td align="char">1</td></tr><tr><td>&#x000a0;Memory clinic</td><td align="char">5</td></tr><tr><td>&#x000a0;Memory clinic and general geriatric clinic</td><td align="char">1</td></tr><tr><td>&#x000a0;Other</td><td align="char">5</td></tr></tbody></table><table-wrap-foot><fn id="tspara0050"><p>Abbreviation: TIA, transient ischaemic
attack</p></fn><fn id="tspara0030"><p>NOTE. Of 84 observational studies, 11 are cross
sectional, and 73 are longitudinal. Data on 12 clinical trials are not
included.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" position="float"><label>Table&#x000a0;3</label><caption><p>Choosing tests to measure cognition in studies and
trials dealing with vascular diseases: a step-based process</p></caption><table frame="hsides" rules="groups"><tbody><tr><td><list list-type="simple"><list-item id="o0010"><label>1)</label><p>Decide to assess cognition
(mandatory)</p></list-item><list-item id="o0015"><label>2)</label><p>Decide whether to assess<list list-type="simple"><list-item id="o0020"><label>a)</label><p>diagnostic outcome measure
(e.g., dementia, cognitive decline, mild cognitive
impairment) and/or</p></list-item><list-item id="o0025"><label>b)</label><p>cognitive measures (i.e., use
domain-specific cognitive tests)</p></list-item></list></p></list-item><list-item id="o0030"><label>4)</label><p>If b, decide which domains to assess,
and</p></list-item><list-item id="o0035"><label>5)</label><p>Which tests to use.</p></list-item></list></td></tr></tbody></table></table-wrap><table-wrap id="tbl4" position="float"><label>Table&#x000a0;4</label><caption><p>Recommendations for research</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Recommendation</th><th>Reason 1</th><th>Reason 2</th><th>Reason 3</th></tr></thead><tbody><tr><td>General</td><td>Vascular and neurodegenerative pathologies are closely related;
vascular pathology is an integral part of the pathological spectrum of
AD, and vascular disease can play an important primary or secondary role
to other pathology in neurodegeneration and dementia.</td><td>Secondary neurodegeneration due to vascular insults is an important
contributor to accumulating structural brain damage and brain
dysfunction.</td><td>Vascular damage can manifest as progressive cognitive, behavioral or
sensorimotor dysfunction, that is, not just stroke.</td></tr><tr><td>Integrated approaches are needed</td><td>Vascular neurodegenerative disorders may present to many different
clinics but are underpinned by a common vascular disorder.</td><td>These clinics should integrate to avoid overlooking the multifaceted
effects of vascular disease on cognition, psychiatric symptoms, and
physical function.</td><td>Clinical practice and research should assess risk factors, clinical,
cognitive, imaging, and physical function.</td></tr><tr><td>Vascular disease is a dynamic and far-reaching process</td><td>Apparently small lesions that may precipitate clinical presentations
have remote effects on other parts of the brain, which increase
neurological and cognitive dysfunction.</td><td>Small lesions are also evidence of a global brain disease and should
be treated as a progressive, global pathology.</td><td>Vascular lesions are not small, individually trivial lesions, without
clinical meaningfulness.</td></tr><tr><td>Always assess vascular risk factors, disease burden, and
outcomes</td><td>Cerebrovascular disease and AD share multiple risk factors, for
example, smoking, hypertension, hyperglycemia, diabetes, and obesity.
Vascular risk factors may have a greater impact in midlife than old
age.</td><td>As an absolute minimum, routinely assess history of cerebrovascular,
peripheral vascular, cardiovascular disease, blood pressure, smoking,
exercise, occupation, and diet, blood lipids, blood glucose.</td><td>Pragmatic approaches can be suitable and avoid overburdening
researchers and participants. Follow-up should continue long
term.</td></tr><tr><td rowspan="2">Cognitive assessments should be performed in, and
relevant to, vascular disease</td><td>Need to be applicable to vascular patients and the environment in
which they typically present.</td><td>Adapted to reflect their specific cognitive deficits and physical
limitations.</td><td>Assess executive function and processing speed in addition to
memory.</td></tr><tr><td>To avoid mistaking lifelong stable traits for late life change,
routinely assess prior cognitive ability (or proxy measures, e.g.,
educational attainment) in any studies of cognition and vascular disease
or other dementias.</td><td>Long-term outcome events, rates, and timings of decline in cognitive
and physical function are needed to power clinical trials and inform
patients and health services more effectively.</td><td>Socioeconomic factors have major influence on vascular disease beyond
that attributed to vascular risk factors alone and should be assessed
routinely.</td></tr><tr><td>Assess physical function across several domains routinely</td><td>Gait, balance, and continence are often affected and should be
assessed routinely in suspected vascular cognitive impairment.</td><td>Simple tests such as &#x0201c;timed up and go&#x0201d; are valuable to assess
physical function.</td><td/></tr><tr><td>Use standard, validated data collection that accounts for vascular
disease</td><td>Agreed core standard data (clinical, cognitive, imaging, biomarkers,
and so forth) and definitions would facilitate future data sharing and
meta-analyses.</td><td>Agreed standards are available, for example, NINDS-CSN Vascular
Cognitive Impairment Harmonization Standards; or STRIVE standards for
neuroimaging.</td><td>Imaging can identify &#x0201c;silent&#x0201d; and symptomatic vascular disease if the
right sequences are used.</td></tr><tr><td>Encourage postmortem brain tissue collection</td><td>Brain tissue from subjects well phenotyped in life, including brain
regions commonly affected by vascular disease, are not widely available;
storing samples frozen, and in paraffin, would facilitate protein, and
gene as well as histological assessments.</td><td>More research is needed on the interaction of AD with cerebrovascular
pathology, the consequences for function of brain networks, and
ultimately how these pathologies evolve and combine to cause clinical
consequences.</td><td>Tissue-imaging analysis of individual lesions is needed to understand
pathological mechanisms.</td></tr><tr><td>Make better use of existing cohort data</td><td>Study registration and public availability of protocols would
facilitate identification of novel and ongoing studies for
meta-analyses.</td><td>Cohorts that assess cerebrovascular disease and include molecular
imaging to assess AD pathology (e.g., by PET amyloid imaging) will help
understand joint pathologies.</td><td>Open data initiatives and databanks would encourage sharing of
existing cohort data.</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: AD, Alzheimer's disease; PET,
positron emission tomography.</p></fn></table-wrap-foot></table-wrap></floats-group></article>